

Supporting Information

Grubbs Metathesis Enabled by a Light-Driven *gem-***Hydrogenation of Internal Alkynes**

Tobias Biberger, Raphael J. Zachmann, and Alois Fürstner*

anie_202007030_sm_miscellaneous_information.pdf

Contents

1.	General Remarks	2
2.	Mechanistic Studies	4
	2.1 Synthesis of a Hoveyda-Grubbs Carbene by gem-Hydrogenation	4
	2.2 Kinetic Profiling of Complex 20	16
	2.3 Hydrogenative Metathesis with H ₂ /D ₂ mixtures	17
	2.4 Headspace Analysis	19
	2.6 The Impact of the UV Irradiation on the Reaction Outcome	31
	2.7 Control Experiment: Orthogonal Entry via a Grubbs Ethylidene Complex	32
3.	Synthesis of Substrates and Precatalysts	34
	3.1 Synthesis of the Substrates	34
	3.2 Synthesis of the Precatalysts	46
4.	Hydrogenative Metathesis Reactions	47
5.	Copies of Spectra	53
6.	References	104

1. General Remarks

All reactions were carried out in flame-dried glassware under argon, ensuring rigorously inert conditions. The solvents were purified by distillation over the indicated drying agents and were stored and handled under argon: CH₂Cl₂ (CaH₂), MeCN (CaH₂), pentane (Na/K alloy), THF (Na/K alloy).

NMR spectra were recorded on Bruker AV400 or AV500 spectrometers at 298 K unless otherwise indicated, with the chemical shift (δ) given in ppm relative to TMS and the coupling constants (J) in Hz. The solvent signals were used as references¹ and the chemical shifts converted to the TMS scale (CD₂Cl₂: δ_H = 5.32 ppm, δ_C = 53.8 ppm; [D₃]-acetonitrile: δ_H = 1.94 ppm, δ_C = 118.26 ppm; [D₆]-acetone: δ_H = 2.05 ppm, δ_C = 29.8 ppm; C₆D₆: δ_H = 7.16 ppm, δ_C = 128.06 ppm).

Unless stated otherwise, all commercially available compounds (abcr, Acros, TCI, Aldrich, Alfa Aesar) were used without further purification.

Hydrogen gas (N50, ≥99.999 Vol.%) was purchased from AirLiquide and was used without further purification. Deuterium gas (99.8 atom% D, 99.995% purity) was purchased from SigmaAldrich. Both hydrogen and deuterium were handled with standard balloon techniques.

IR spectra were recorded on Alpha Platinum ATR spectrometer (Bruker) at room temperature, wavenumbers (\tilde{v}) are given in cm⁻¹.

Mass spectrometric samples were analyzed using the following instruments: MS (EI): Finnigan MAT 8200 (70 eV), ESI-MS: Bruker ESQ3000, accurate mass determinations: Bruker APEX III FT-MS (7 T magnet) or MAT 95 (Finnigan).

GC-MS was performed with a Shimadzu GCMS-QP2010 Ultra instrument.

Headspace GC-FID samples were measured on an Agilent Technology 6890 or 7890 instrument with a 30 m HP-plot Al_2O_3 column (0.25 mm Ø, 5 μ m film) using H_2 as the carrier gas. Headspace GC/MS samples were analyzed on an Agilent Technology 7890A instrument with AT 5975C MSD detection.

Photolysis experiments were performed in a self-made apparatus (Figure S-1), consisting of an aluminum box with a circular arrangement of 8 UV-A lamps (Philips Fluorescent lamps TUV PL-S 9W/2P, $\lambda = 340-380$ nm (Figure S-2) at 6 cm distance to the quartz-Schlenk tube. The temperature in the apparatus typically rises to 45 °C over the course of 1 h.




Figure S-1. Reaction set-up





Figure S-2. Emission spectrum of the UV lamps

2. Mechanistic Studies

2.1 Synthesis of a Hoveyda-Grubbs Carbene by *gem*-Hydrogenation

1-Isopropoxy-2-(prop-1-yn-1-yl)benzene (19)



1-Ethynyl-2-isopropoxybenzene (250 mg, 1.56 mmol)² was dissolved in THF (5 mL) and the resulting solution cooled to -78 °C. *n*-BuLi (1.6 M in hexanes, 1.07 mL, 1.71 mmol) was added dropwise over 5 min and the mixture was stirred for 30 min. Methyl iodide (147 μ L, 2.35 mmol) was added and stirring was

continued at room temperature for 15 h. Sat. aq. NH₄Cl (4 mL), *tert*-butyl methyl ether (10 mL) and water (2 mL) were added and the layers were separated. The aqueous layer was extracted with *tert*-butyl methyl ether (3 × 20 mL) and the combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (silica, pentane/*tert*-butyl methyl ether 100:1) to provide the title compound as a colorless oil (200 mg, 74%). ¹H NMR (400 MHz, CDCl₃) δ 7.36 (dd, J = 7.9, 1.8 Hz, 1H), 7.22 – 7.12 (m, 1H), 6.93 – 6.83 (m, 2H), 4.55 (hept, J = 6.1 Hz, 1H), 2.09 (s, 3H), 1.37 (d, J = 6.1 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 158.8, 133.8, 128.8, 120.9, 115.5, 89.7, 76.3, 72.1, 22.3, 4.8. IR (film) \tilde{v} 2977, 1594, 1482, 1444, 1383, 1372, 1262, 1102, 974, 748 cm⁻¹. HRMS (ESI⁺) for C₁₂H₁₄O [M]⁺: calcd. 174.10388; found: 174.10392.

Complex 20.



A flame-dried quartz Schlenk tube was charged under argon with [(IMes)(p-cymene)RuCl₂] (102 mg, 167 µmol), alkyne **19** (28.2 mg, 167 µmol) and THF (6 mL). The Schlenk tube was closed with a septum and then transferred into the photolysis apparatus (Figure S-1). A hydrogen-filled balloon was connected to a needle which was pierced through the septum. The Schlenk tube was flushed with hydrogen for 2 min through an outlet


cannula (the cannula did not reach into the solution to ensure that only the head space of the tube was flushed). After the first 10 seconds of flushing with hydrogen, the light source was switched on and the reaction mixture was stirred for 30 min under hydrogen atmosphere. After cooling to room temperature, all volatile components were removed under high vacuum. The remaining crude material was suspended in pentane (10 mL) and the suspension was vigorously stirred for



5 min. The supernatant was removed via a filter canula and the dark green filtrate was collected. This trituration procedure was repeated twice and the combined filtrates were evaporated. The remaining material was purified by flash chromatography (silica, CH₂Cl₂→ CH₂Cl₂/MeOH 25:1). The green band was collected and the solvent evaporated to provide the title compound (34.1 mg, 31%) as a dark green oil. Dark green needleshaped crystals suitable for X-ray diffraction were grown by slow evaporation of CH₂Cl₂/pentane solutions in a constant stream of argon.

¹H NMR (600 MHz, C_6D_6) δ 7.35 (dd, J = 7.7, 1.6 Hz, 1H), 7.10 (ddd, J =8.5, 7.3, 1.6 Hz, 1H), 6.88 (s, 4H), 6.60 (td, J = 7.7, 7.3, 0.9 Hz, 1H), 6.43

(d, J = 8.3 Hz, 1H), 6.17 (s, 2H), 4.57 (hept, J = 6.2 Hz, 1H), 2.62 (q, J = 7.5 Hz, 2H), 2.40 (s, 12H), 2.20 (s, 6H), 1.12 (d, J = 6.2 Hz, 6H), 0.97 (t, J = 7.5 Hz, 3H). ¹³C NMR (151 MHz, C₆D₆) δ 314.5, 174.9, 154.6, 146.7, 138.9, 138.5, 136.0, 129.0, 128.5, 124.6, 121.0, 114.3, 112.4, 74.3, 51.5, 21.2, 20.8, 19.5, 6.2. IR (film) \tilde{v} 2961, 2921, 2865, 1573, 1483, 1450, 1395, 1304, 1259, 1224, 1160, 1078, 1012, 936, 922, 850, 791, 751, 698, 665, 614, 593, 579 cm⁻¹. HRMS (ESI+) for $C_{33}H_{40}Cl_2N_2ORu$ [M]⁺: calcd. 652.15553; found: 652.15557.



373.21380.

A second fraction collected during flash chromatography consisted of compound **21** (colorless oil, 16.1 mg, 55%). ¹H NMR (600 MHz, CDCl₃) δ 7.30 (dd, J = 7.5, 1.8 Hz, 1H), 7.21 (td, J = 7.7, 1.8 Hz, 1H), 6.97 (td, J = 7.5, 1.1 Hz, 1H), 6.93 (dd, J = 8.2, 1.2 Hz, 1H), 6.86 (s, 1H), 4.50 (hept, J = 6.0 Hz, 1H), 2.14 (s, 2H), 1.36 (d, J = 6.1 Hz, 5H). ¹³C NMR (151 MHz, CDCl₃) δ 156.1, 138.3, 131.0, 129.4, 127.6, 123.2, 120.3, 114.8, 71.3, 22.3, 15.9. IR (film) \tilde{v} 2975, 2931, 1594, 1481, 1449, 1383, 1372, 1287, 1238, 1120, 957, 749 cm⁻¹. HRMS (ESI⁺) for $C_{24}H_{30}O_2Na$ [M]⁺: calcd. 373.21349; found:





Figure S-3. Structure of complex **20** in the solid state in two different orientation; hydrogen atoms (except on the ethyl substituent) are omitted for clarity


X-ray Crystal Structure Analysis of Complex 20: C_{33} H₄₀ Cl₂ N₂ O Ru, M_r = 652.64 g · mol⁻¹, green plate, crystal size 0.127 x 0.067 x 0.013 mm³, triclinic, space group P7 [2], a = 8.5880(5) Å, b = 11.2933(6) Å, c = 17.1714(9) Å, α = 99.455(2)°, β = 92.749(2)°, γ = 107.076(2)°, V = 1562.16(15) ų, T = 100(2) K, Z = 2, D_{calc} = 1.387 g · cm³, λ = 0.71073 Å, μ (Mo- K_{α}) = 0.701 mm⁻¹, analytical absorption correction (T_{min} = 0.95, T_{max} = 0.99), Bruker-AXS Kappa Mach3 diffractometer with APEX-II detector and IµS micro focus X-ray source, 1.208 < θ < 33.141°, 67324 measured reflections, 11891 independent reflections, 10420 reflections with I > 2 σ (I), R_{int} = 0.0411. S = 1.046, 361 parameters, residual electron density +1.5 (0.83 Å from Si3) / -0.7 (0.72 Å from Si3) e · Å⁻³. The structure was solved by SHELXT and refined by full-matrix least-squares (SHELXL) against F² to R_1 = 0.032 [I > 2 σ (I)], wR_2 = 0.073. **CCDC-2004044**.





Atom	δ (ppm)	J	COSY	HSQC	нмвс	NOESY	Atom	δ (ppm)	J	COSY	HSQC	нмвс	NOESY
1 C	6.18			1	2		11' C	21.16	6.20(10H)		11'	10, 11	
Н3	0.97	7.50(2)	2	1	2, 3	2, 5	НЗ	1.12		10	11'	10, 11	8, 10
2 C	51.54			2	1		12 C	174.84				4, 13	
H2	2.62	7.50(1)	1	2	1, 3, 4	1, 5	13 C	124.57			13	13	
3 C	314.51				1, 2, 5								
4 C	146.73				2, 6, 8		Н	6.17			13	12, 13	
5 C	114.26			5	7		14 C	136.01				16, 16', 18, 18', 19'	
Н	7.35	1.60(7), 7.70(6)	6	5	3, 7, 9	1, 2, 6	15 C	138.45				18	
6 C	121.02			6	8		15' C	138.45				18'	
н	6.60	7.70(5), 7.30(7)	5, 7	6	4, 8, 9	5, 7	16 C	129.02			16	16', 18, 19'	
7 C	128.50			7	5		н	6.88			16	14, 16', 18,	18, 19', 19
Н	7.10	1.60(5), 8.20(8), 7.30(6)	6, 8	7	5, 9	6, 8	16' C	129.02			16'	19 16, 18', 19'	19""
8 C	112.36			8	6								
н	6.43	8.20(7)	7	8	4, 6, 9	7, 10, 11, 11	Н	6.88			16'	14, 16, 18', 19	18', 19'
9 C	154.58	0.20(1)	Ė		5, 6, 7, 8, 10		17 C	138.90				19'	
10 C	74.33			10	11, 11'		18 C	19.50			18	16	
н	4.57	6.20(11'C), 6.20(11)	11, 11	10	9, 11, 11'	8, 11, 11'	H3	2.40			18	14, 15, 16	16
11 C	21.16	0.20(11)		11	10, 11'		18' C	19.50			18'	16'	
Н3	1.12	6.20(10)	10	11	10, 11'	8, 10	Н3	2.40			18'	14, 15', 16'	16'
							19 C	20.76			19', 19", 19'''	16, 16'	
							Н3	2.20			19	14, 16, 16', 17	16, 16'


P-ID: ML0000000
Measured on: 16/01/2020
Measured on: 16/01/2020
Measured on: 16/01/2020
Measured on: 16/01/2020
Client: Toblas Biberger
Group: Fürster
Spectroscopist: Leutzsch
Analysed on: 16/01/2020
Analysed by: Leutzsch
Amount: 10 mg
Solvent: C6D6
Reference: solvent
Temperature: 298 K
Spectrometer: AV600nece


Solvent: Cooper Solvent Solve













Side product 21

After analysis the NMR data supports the following structure:


User Report


		Assignm ents				Assignm ents						
H ₃ C 10, 19 5 4 3	Aton	Chemical Shift	COSY	HSQC	нмвс	NOESY	Atom	Chemical Shift	COSY	HSQC	нмвс	NOESY
	1 C	130.985		1	3		7' C	123.234		7	1', 9, 9'	
CH ₃	н	7.296	2	1	3, 5, 7	2, 9	н	6.859		7	1', 5', 8'	
ĺl '	1' C	130.985		1'	3', 7'		8 C	138.266				12'
H ₃ C 8'	н	7.296	2'	1'	3', 5', 7'	2', 9'						
9 8 CH ₃	2 C	120.270		2	4		8' C	138.266			7, 7', 9, 9'	
-15 47	н	6.973	1, 3	2	4,6	1, 3	9 C	15.846		9		
2 CH ₃	2' C	120.270		2'	4'		H3	2.143		9	7', 8'	1,7
1 1	Н	6.973	1', 3'	2'	4', 6'	1', 3'	9' C	15.846		9'		
3 /5 /10	3 C	127.587		3	1		H3	2.143		9'	7', 8'	1', 7'
14 O CH ₃	н	7.211	2,4	3	1,5	2,4	<u> </u>			-		
25 12	3' C	127.587		3'	1'			71.224		10	11	
	н	7.211	2', 3',	3'	1', 5'	2', 4'	H	4.505	11, 12		11, 12	4
			4'		_		10'C	71.224		10'	11', 12'	
e to the high symmetry and flexibility of the molecule, no ormation could be obtained about the double bond geometry. It	is H	6.932	3	4	2, 5, 6	3, 10,	н	4.505	11', 12'	10'	5', 11', 12'	4'
ner all-cis or all-trans	'	0.532	,	7	2, 3, 6	11, 12	11 C	22.231		11	10, 12	
(ray structure could solve that problem. Maybe EI-MS can also	4' C	114.751		4'	2'		H3	1.357	10	11	10, 12	4,7
p to solve that question.	н	6.932	3'	4'	2', 5', 6'	3', 10', 11', 12'	11'C	22,231		11'	10', 12'	
	5 C	156.048			1, 3, 4		Н3	1.357	10'	11'	10', 12'	4', 7'
ID: ML00000 rasured on: 16/10/2019	5' C	156.048		-	1', 3',		12 C	22.231		12	10, 11	
IFFRE: BIU-BB-459-01 IA#: 3314	, -	130.040			4', 7',		H3	1.357	10	12	11	4,7
ent: Tobias Biberger	6 C	129,409	-	-	2.4		12'C	22.231		12'	10', 11'	
oup: Fürstner ectroscopist: Leutzsch							H3	1.357	10'	12'	10', 11'	4', 7'
alysed on: 16/10/2019	6' C	129.409			2', 4'		19 O					
alysed by: Leutzsch rount: 15 mg	7 C	123.234		7	1		23 O					
lvent: CDCl3 ference: solvert	н	6.859		7	8'	9, 11, 12	_					
mperature: 298 K ectrometer: AV600a bbe: 244896 0147 (CP TCI 60053 H-C/N-D-05 Z)		1										





50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 13C (ppm)





2.2 Kinetic Profiling of Complex 20

In order to characterize complex **20** further, we made use of a standard method to assess the catalytic performance of olefin metathesis catalyst developed by Grubbs et al.³ To this end, the ring closing metathesis of diallylmalonate (**22**) was carried out with complex **20** and the commercially available Grubbs II and Hoveyda-Grubbs II catalysts for comparison.

In an argon-filled glovebox, an NMR tube with a screw cap septum top was charged with a stock solution of the corresponding complex in CD_2Cl_2 (1 mol%, 0.5 mL). The sample was brought out of the glovebox and equilibrated at 30°C in the NMR machine before diallylmalonate **22** (12.8 μ L, 53.5 μ mol) was added via a Hamilton syringe. The NMR tube was quickly shaken and inserted in the NMR probe. Data points were collected over 20 mins and the acquired raw data were processed in MestReNova with the ReactionMonitoring-plugin (Figure S-4).




Figure S-4. RCM of diallylmalonate 22 with formation of product 23 ([Ru-1] = complex 20)

All tested catalysts exhibit similar rates at 1 mol% catalyst loading up to 60% conversion. Figure S-4 shows that after this point the Grubbs II and the Hoveyda-Grubbs II catalyst convert the substrate quantitatively into the product, whereas the reaction catalyzed by 20 stalled at \approx 60% conversion. However, this catalysts fully converts the substrate into product without losing activity at a loading of 3 mol%.


2.3 Hydrogenative Metathesis with H₂/D₂ mixtures

A 1:1 mixture of H_2 and D_2 was prepared by using a gas-tight 10 mL Hamilton syringe: a gas volume of 5 mL was taken out of a balloon filled with H_2 and of a second balloon filled with D_2 : the Hamilton syringe was then shaken to ensure mixing of the two gases.

A flame-dried quartz Schlenk tube was charged with [(IPr)(p-cymene)RuCl₂] (13.8 mg, 200 μmol, 10 mol%), enyne **1b** (44.1 mg, 0.2 mmol) and toluene (2.0 mL, 0.1 M). The Schlenk tube was closed with a septum and then transferred into the photolysis apparatus. The total volume of 10 mL H₂/D₂ was then flushed through the quartz Schlenk tube using an outlet canula. This procedure was repeated nine times to fully exchange the argon atmosphere for a H₂/D₂ atmosphere. At this point, the light source was switched on and the mixture was stirred for 60 min. For work-up, the mixture was diluted with pentane (5 mL) and filtered through a short silica pad. The filtrate was evaporated and the remaining crude material was purified by flash chromatography (silica, pentane/tert-butyl methyl ether 50:1) to provide product **2** (28.1 mg, 72%) as a colorless oil. The identity and composition of

The isotopomer ratio was determined to be $[D_0]:[D_1]:[D_2] = 42:34:24$. The formation of significant quantities of an $[D_1]$ isotopomer is suggestive of a non-concerted hydrogen transfer mechanism.


the different isotopomers was established by ¹H and ¹³C NMR spectroscopy.



From ¹³ C	Integral			%Content				
Atom	H2	HD	D2	%Content				
1	1.8878	1.4529	1	43%	33%	23%		
7	1.8184	1.4542	1	43%	34%	23%		
8.8'	1.6476	1.4036	1	41%	35%	25%		
4	1.5538	1.3524	1	40%	35%	26%		
		Average		41.6%	34.2%	24.2%		
			error	1.7%	0.6%	1.2%		

2.4 Headspace Analysis

A flame-dried quartz Schlenk tube was charged with $[(IPr)(p-cymene)RuCl_{21}(13.8 \text{ mg}, 0.02 \text{ mmol}, 10 \text{ mol}\%)$, the corresponding enyne **1a** or **1b** (200 µmol) [for the crossover experiment, enyne **1a** and **1b** (100 µmol, each)] and toluene (2 mL, 0.1 M). The Schlenk tube was closed with a septum and then transferred into the photolysis apparatus. A hydrogen-filled balloon was equipped with a needle which was pierced through the septum and the Schlenk tube was flushed with hydrogen for 2 min through an outlet cannula (the cannula did not reach into the solution to ensure that only the head space of the tube was flushed). After the first 10 seconds of flushing with hydrogen, the light source was switched on and the mixture was stirred for 60 min under hydrogen atmosphere. At this point, a gas-tight 1 mL Hamilton Syringe was used to take 500 µL aliquots of the gas in the headspace of the Schlenk tube and the samples were analyzed by GC. Retention times and fragmentation patterns of authentic samples of various gases (Phillips No.40 + methane, ethane and ethylene) were used to unambiguously assign the structure of the volatile compounds formed during the hydrogenative metathesis reaction.



The presence of alkanes in the headspace is explained by reduction of the alkenes primarily formed by the same catalyst system. Terminal alkenes tend to be reduced (much) faster than more hindered internal alkenes, which likely explains why ethane is by far the major component of the C_2 fraction.

S19





Figure S-5. Possible explanation for the formation of products with odd carbon numbers in the headspace


Hydrogenative metathesis of enyne **1b** yields 95% (NMR) of cyclopentene **2**. Analysis of the headspace by GC shows that the major species are C₄-products, namely butenes and butane. Interestingly, significant amounts of C₃- and C₅-products are detected as well: their formation is attributed to an isomerization/carbene formation/cross dimerization sequence (see Figure S-5). It has previously been shown that the 12e-fragment [(IPr)RuCl₂] generated under the reaction conditions is an effective catalyst for alkene isomerization.⁴ Moreover, DFT calculations suggested that [(IPr)RuCl₂] is able to activate a terminal alkene to generate, via a bimolecular transition state, two new ruthenium carbenes.⁴ Cross-dimerization of these "tertiary" ruthenium carbenes with the "secondary" ruthenium carbene explains the observation of C₃- and C₅-products.



The model reaction was also run with 5 mol% and 20 mol% catalyst loading. Headspace GC analysis showed that the proportion of C_4 and C_3 compounds is essentially independent of the loading. However, the ratio between unsaturated and saturated compounds does change in that the proportion of alkanes is significantly increased at higher loading; this finding is again in line with a secondary hydrogenation process.


It is of note that Fogg, Jensen and coworkers have recently studied a pyridine-stabilized ruthenium ethylidene complex, which decomposes via bimolecular coupling to give a mixture of butene,

pentene and propene in a 2:1:1 ratio.⁵ Whilst this observation is qualitatively similar to our observations, we note that pentenes and pentane are underrepresented (relative to propane/propene) in our study. The difference might be explained by the fact that different analytical tools were used (GC/MS versus NMR); since pentenes/pentane are less volatile than propene/propane, they might be underrepresented in the gas phase. Efforts to quantify the pentenes by NMR spectroscopy in the liquid phase were unsuccessful due to severe signal overlap with product 2. Moreover, one might conceive that dimerization of a propylidene complex with an ethylidene complex is (somewhat) slower than the dimerization of a propylidene complex with a methylidene complex.



Hydrogenative metathesis with a 1:1 mixture of enynes $\mathbf{1a}^6$ and $\mathbf{1b}$ confirms the bimolecular decomposition of the secondary carbene complex. The *increased* amount of C₃-products and concomitant *decrease* of C₄- and C₂-products strongly supports the notion that bimolecular alkylidene coupling is operative. The fact that the C₂:C₃:C₄ ratio is not 1:2:1, as statistically expected from such a crossover experiment, is ascribed to different rates of alkylidene coupling and to the necessary isomerization events discussed above.

Headspace analysis (GC) @ 10 mol% catalyst loading



Sequenz date:

25.02.20

Processing M.: Übersicht BIU-BB

Report-File:

623-01

Auswertung ohne Lösungsmittel (Toluol-d8)

Zuordnung mit Vergleichssubstanzen (Gasmischung Phillips No.40 und Methan, Ethan, Ethan)

No.	Ret.Time	area-%	Peak Name
	min	%	
1	0,94	0,09	Methan
2	1,01	1,31	Ethan
4	1,26	29,19	Propan
5	1,62	1,22	Propen
7	2,18	35,52	n-Butan
8	3,37	10,50	trans-2-Buten
9	3,51	0,51	1-Buten
10	3,88	0,02	iso-Buten
11	4,19	3,82	cis-2-Buten
12	4,98	0,07	
13	5,21	0,01	iso-Pentan
14	5,77	6,04	÷.
16	8,57	0,02	
17	9,51	3,28	trans-2-Penten
18	10,76	0,20	1-Penten
19	11,26	0,01	
20	11,91	0,81	cis-2-Penten
25	14,09	0,01	
26	15,13	0,96	
28	16,45	0,01	
30	17,45	0,24	¥
31	17,62	0,07	
32	17,73	0,01	
33	17,76	0,01	
34	17,86	0,64	
36	18,17	0,04	
38	18,57	0,01	

Page 2-2

No.	Ret.Time	area-%	Peak Name
	min	%	
39	18,67	0,01	
40	18,75	0,04	
41	19,17	0,18	*:
44	20,00	0,01	
47	21,57	0,14	
48	23,13	0,09	
49	23,39	4,20	
50	24,14	0,02	
51	24,55	0,03	
52	24,67	0,01	
53	24,80	0,01	
54	24,91	0,01	
57	25,32	0,01	
58	25,55	0,03	
59	25,68	0,02	
60	25,89	0,03	
61	26,01	0,01	
63	26,69	0,44	
64	26,99	0,01	
66	27,98	0,02	

19 peaks out of 66 (total area percentage=

0,06 %) are below threshold.

Instrument parameters:


Column: 29,5 m HP-Plot/Al2O3 0,25/5,0df G/425 Temperature: 220/ 80, 10 min iso 6/min 180, 5 min iso/ 350 Gas:

0,80 bar

Sample size: 450,0 µL

V.Diell





Auswertung ohne Lösungsmittel (Toluol-d8)

Zuordnung mit Vergleichssubstanzen (Gasmischung Phillips No.40 und Methan, Ethan, Ethan)

No.	Ret.Time	area-%	Peak Name
	min	%	
1	0,94	0,08	Methan
2	1,01	63,30	Ethan
3	1,07	1,77	Ethen
4	1,26	3,27	Propan
5	1,62	1,71	Propen
7	2,04	0,02	iso-Butan
8	2,20	2,32	n-Butan
9	3,38	3,08	trans-2-Buten
10	3,51	0,26	1-Buten
11	3,89	0,08	iso-Buten
12	4,20	1,27	cis-2-Buten
13	4,99	0,10	
14	5,22	0,01	iso-Pentan
15	5,82	1,26	%
16	8,60	0,05	
17	9,57	1,17	trans-2-Penten
18	10,77	0,16	1-Penten
19	11,28	0,02	
20	11,94	0,32	cis-2-Penten
21	13,09	0,01	
22	13,45	0,01	
23	14,13	0,02	
24	15,16	0,50	29
25	15,96	0,01	
26	16,48	0,01	
27	17,48	0,17	
28	17,65	0,23	

Page 2-2

No.	Ret.Time	area-%	Peak Name
	min	%	
29	17,79	0,03	
30	17,88	0,45	ž.
31	18,19	0,13	
32	18,47	0,02	
33	18,60	0,04	
34	18,69	0,02	
35	18,77	0,03	
36	19,19	0,13	2.
37	19,75	0,02	
38	19,83	0,03	
39	20,03	0,05	
40	21,59	0,17	1020
41	23,15	0,11	
42	23,40	15,14	
43	24,15	0,02	
44	24,57	0,04	
45	24,69	0,02	
46	24,84	0,04	
47	24,93	0,04	
48	25,12	0,02	
49	25,17	0,01	
50	25,35	0,05	
51	25,58	0,14	
52	25,70	0,05	
54	25,91	0,09	
55	26,02	0,04	
56	26,70	1,81	19
57	27,00	0,02	
58	27,62	0,04	

peaks out of 58 (total area percentage=

0,00 %) are below threshold.

Instrument parameters:


Column: 29,5 m HP-Plot/Al2O3 0,25/5,0df G/425 220/ 80, 10 min iso 6/min 180, 5 min iso/ 350 0,80 bar H2 Temperature: Gas: H2

Sample size:

450,0 µL

V. Diet





Auswertung ohne Lösungsmittel (Toluol-d8)

Zuordnung mit Vergleichssubstanzen (Gasmischung Phillips No.40 und Methan, Ethan, Ethan)

No.	Ret.Time	area-%	Peak Name
	min	%	
1	0,94	0,06	Methan
2	1,00	17,01	Ethan
3	1,06	0,05	Ethen
4	1,25	34,99	Propan
5	1,62	9,83	Propen
6	2,04	0,01	iso-Butan
7	2,19	6,68	n-Butan
8	3,36	14,29	trans-2-Buten
9	3,51	0,98	1-Buten
10	3,89	0,06	iso-Buten
11	4,19	5,43	cis-2-Buten
12	4,99	0,04	
13	5,23	0,01	iso-Pentan
14	5,82	1,03	si .
15	8,61	0,08	
16	9,56	2,55	trans-2-Penten
17	10,81	0,24	1-Penten
18	11,31	0,02	
19	11,95	0,69	cis-2-Penten
21	14,13	0,01	
22	15,17	0,10	G.
23	15,97	0,01	
25	16,48	0,01	
27	17,49	0,13	ă.
28	17,65	0,11	
29	17,74	0,01	
30	17,79	0,01	

Page 2-2

No.	Ret.Time	area-%	Peak Name
	min	%	
31	17,89	0,37	
32	18,20	0,05	
34	18,60	0,02	
35	18,70	0,02	
36	18,78	0,02	
37	19,20	0,11	
40	20,03	0,01	
44	21,60	0,02	500
45	23,16	0,04	
46	23,41	4,40	300
47	24,17	0,01	
48	24,58	0,01	
50	24,94	0,01	
51	25,12	0,01	
52	25,36	0,01	
54	25,58	0,02	
55	25,71	0,01	
56	25,92	0,02	
57	26,04	0,01	
59	26,72	0,35	3
61	27,65	0,01	
62	28,01	0,01	

peaks out of 62 (total area percentage=

0,04 %) are below threshold.

Instrument parameters:


Column:

HP-Plot/Al2O3 0,25/5,0df G/425

H2

Temperature: 220/ 80, 10 min iso 6/min 180, 5 min iso/ 350 Gas: 0,80 bar

Sample size: 450,0 µL



2.5 VT NMR Studies of [(NHC)(p-cymene)RuCl₂] Complexes

Ru-CI
rt to 100 °C,
$$C_6D_6$$

R = Dipp: 56% (nmr yield)
R = Mes: 37% (nmr yield)

A flame-dried pressure NMR tube was charged with a solution of the corresponding complex $[(NHC)(p\text{-cymene})RuCl_2]$ (15 µmol) in $[D_6]$ -benzene (500 µL). The NMR tube was inserted into the NMR probe head and spectra were acquired in a temperature range from 25 °C to 100 °C (10 °C increments).




Figure S-6. Exchange of the *p*-cymene ligand in [(IPr)(η^6 -cymene)RuCl₂] by C₆D₆ under themal conditions in the dark




Figure S-7. Exchange of the *p*-cymene ligand in [(IMes)(η^6 -cymene)RuCl₂] by C₆D₆ under themal conditions in the dark

We infer that ligand exchange with $[(IPr)(p\text{-cymene})RuCl_2]$ is more efficient compared to $[(IMes)(p\text{-cymene})RuCl_2]$ as evidenced by the higher NMR yield. In both cases, the ligand displacement starts at 60-70 °C.

2.6 The Impact of the UV Irradiation on the Reaction Outcome




Figure S-8. Comparison of the ¹H NMR spectra of the crude reaction mixture formed with photochemical (top) or themal (100°C, bottom) activation: region of the olefinic signals




Figure S-9. Comparison of the ¹H NMR spectra of the crude reaction mixture formed with photochemical (top) or themal (100°C, bottom) activation: region of the –OMe signal

2.7 Control Experiment: Orthogonal Entry via a Grubbs Ethylidene Complex

[1,3-Bis(2,6-diisopropyl-phenyl)-2-imidazolidinylidene]dichloro(benzylidene)bis(pyridine)-ruthenium


(1,3-Bis(2,6-diisopropylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)-(tricyclohexylphosphine)ruthenium (1.00 g, 1.93 mmol) was weighed into a Schlenk tube and neat pyridine (3.90 mL, 48.3 mmol) was added at room temperature, causing an immediate color change from purple to dark green. After 15 min, pentane (20 mL) were carefully layered onto the solution and the Schlenk

tube was sealed and stored in a fridge for 18 h. The precipitated light green crystals were filtered off with a filter canula, washed with pentane (3 x 15 mL) and dried under high vacuum to provide the compound as a light green powder (830 mg, 95%). 1 H NMR (400 MHz, $C_{6}D_{6}$) δ 19.82 (s, 1H), 8.70 (d, J = 4.9 Hz, 2H), 8.36 (d, J = 5.4 Hz, 2H), 7.99 – 7.86 (m, 2H), 7.33 – 7.22 (m, 2H), 7.21 – 7.10 (m, 5H), 6.93 – 6.82 (m, 3H), 6.73 (s, 2H), 6.55 (t, J = 6.5 Hz, 2H), 6.38 (t, J = 7.7 Hz, 1H), 6.05 (t, J = 6.7 Hz, 2H), 3.66 (s, 4H), 1.46 (s, 12H), 1.10 (d, J = 6.8 Hz, 12H). 13 C NMR (101 MHz, $C_{6}D_{6}$) δ 314.0, 186.9, 153.2, 152.7, 150.6, 147.9, 137.7, 135.5, 135.0, 130.4, 130.2, 129.6, 126.2, 124.3, 123.2, 122.9, 28.8, 26.5, 23.3.

[1,3-Bis(2,6-diisopropyl-phenyl)-2-imidazolidinylidene]dichloro(ethylidene)bis(pyridine)-ruthenium (24).⁷

[1,3-Bis(2,6-diisopropyl-phenyl)-2-imidazolidinylidene]dichloro(benzylidene)bis(3-bromopyridine)ruthenium (50 mg, 61.7 μ mol) was dissolved in C₆D₆ (1.5 mL) and the resulting solution was cooled to 5 °C (just above the melting point of benzene). (2 \mathbb{Z})-Butene was bubbled through the mixture for 1 min, causing a color change

from dark green to dark yellow within 3 min. The solution was then cooled to 0 °C to freeze the benzene, which was then sublimed off under high vacuum. The residue was then redissolved in cold pentane and the pentane was again removed under high vacuum to azeotropically remove traces of residual methyl styrene that was formed during the reaction. Drying under high vacuum afforded the compound as a yellow-brown solid (42 mg, 93%). The complex decomposes readily at ambient temperature. 1 H NMR (400 MHz, C_6D_6) δ 19.70 (q, J = 6.0 Hz, 1H), 8.75 (d, J = 5.1 Hz, 4H), 7.28 – 7.06 (m, 12H), 6.72 (s, 2H), 3.89 – 3.49 (m, 4H), 1.89 (d, J = 6.0 Hz, 3H), 1.58 (d, J = 6.5 Hz, 12H), 1.08 (d, J = 7.0 Hz, 12H). Due to the thermal instability of the sample, a ^{13}C NMR spectrum could not be recorded.



A flame-dried quartz Schlenk tube was charged with enyne **1a** (66.0 mg, 0.31 mmol) and toluene (1 mL). The Schlenk tube was closed with a septum and then transferred into the photolysis apparatus. A hydrogen-filled balloon was connected to a needle which was pierced through the septum and the Schlenk tube was flushed with hydrogen for 2 min through an outlet cannula (the cannula did not reach into the solution to make sure that only the head space of the tube was flushed). The ethylidene complex **24** (42.0 mg, 20 mol%) in toluene (2 mL) was added via syringe and the resulting mixture was stirred for 60 min under H₂ atmosphere. The mixture was diluted with pentane (5 mL) and then filtered through a short pad of silica. The filtrate was evaporated and the residue was analyzed by ¹H NMR spectroscopy, which showed the formation of product **2** in 64% NMR yield; the analytical data of this compound are compiled below.

3. Synthesis of Substrates and Precatalysts

3.1 Synthesis of the Substrates

$$S1$$
 $S2$ $S3$ H $S4$ $S5$

The alkynes S1,¹³ S2,¹³ S3,¹³ S4⁸ and (*E*)-6-bromohex-2-ene (S5)⁹ were prepared according to literature procedures.

(*E*)-7-Bromohept-2-ene (S6)


A solution of (*E*)-hept-5-en-1-ol (498 mg, 4.36 mmol)¹⁰ and CBr₄ (1.60 g, 4.82 mmol) in CH₂Cl₂ (25 mL) was cooled to 0 °C before PPh₃ (1.26 g, 4.82 mmol) was added in portions over a period of 30 min under vigorous stirring. Once the addition was complete, stirring was continued for another 2.5 h at ambient temperature. The mixture was concentrated to half of the volume under reduced pressure and then slowly added to hexanes (250 mL) with vigorous stirring. After 5 min, the precipitate was filtered off and the filtrate was concentrated under reduced pressure. Purification of the residue by flash chromatography (silica, pentane) provided the title compound as colorless oil (328 mg, 42%). ¹H NMR (400 MHz, CDCl₃) δ 5.71 – 5.20 (m, 2H), 3.41 (t, J = 6.8 Hz, 2H), 2.05 – 1.96 (m, 2H), 1.90 – 1.81 (m, 2H), 1.64 (dq, J = 4.3, 1.2 Hz, 3H), 1.56 – 1.44 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 130.7, 125.6, 34.0, 32.4, 31. 8, 28.2, 18.1. IR (film) \tilde{v} 2961, 2933, 2855, 1452, 1438, 1250, 1226, 964, 645, 562 cm⁻¹. HRMS (EI) for C₇H₁₃Br [M]⁺: calcd. 176.01958; found: 176.01953.

1-Methoxy-1-(prop-1-yn-1-yl)cyclohexane (S7)

Sodium hydride (381 mg, 15.9 mmol) was added in portions over 5 min to a solution of 1-(1-propynyl)cyclohexanol (2.00 g, 14.5 mmol) in THF (72 mL) at 0 °C. The suspension was stirred for 30 min before dimethyl sulfate (1.53 mL, 16.2 mmol) was added dropwise and stirring was continued overnight at room temperature. Water (100 mL) was carefully added and the mixture was extracted with pentane (3 x 50 mL). The combined organic fractions were washed with brine, dried over Na₂SO₄ and concentrated under reduced

pressure (40 °C, 100 mbar). The residue was dissolved in pentane/diethyl ether (50:1) and the turbid solution filtered through a short silica plug. After evaporation of all volatile materials, the compound was purified by vacuum distillation (34 mbar, bath temperature: 135 °C, head temperature 100 °C) which yields the title compound as a colorless liquid (2.10 g, 95%). ¹H NMR (400 MHz, CDCl₃) δ 3.34 (s, 3H), 1.87 (s, 3H), 1.84 – 1.78 (m, 2H), 1.67 – 1.41 (m, 8H). ¹³C NMR (101 MHz, CDCl₃) δ 81.6, 80.3, 74.0, 50.5, 37.0, 25.6, 22.9, 3.6. IR (film) \tilde{v} 2933, 2856, 1447, 1294, 1185, 1172, 1145, 1091, 1086, 925 cm⁻¹. HRMS (ESI+) for C₁₀H₁₆ONa [M+Na]+: calcd. 175.10935; found: 175.10935.

1-Bromo-2-(3-methoxy-3-methylbut-1-yn-1-yl)benzene (S8)



Sodium hydride (141 mg, 5.89 mmol) was added to a solution of 4-(2-bromophenyl)-2-methylbut-3-yn-2-ol (880 mg, 3.68 mmol)¹¹ in DMF (15 mL) at 0 °C and the resulting mixture was stirred for 30 min at this temperature. Methyl iodide (791 mg, 0.34 mL, 5.52 mmol) was added and stirring was

continued for 15 h at ambient temperature. Water (20 mL) was introduced and the mixture was extracted with *tert*-butyl methyl ether (3 x 20 mL). The combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. Purification of the residue was achieved by flash chromatography (silica, pentane/*tert*-butyl methyl ether 50:1) to yield the title compound (727 mg, 78%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.61 – 7.55 (m, 1H), 7.47 – 7.43 (m, 1H), 7.28 – 7.22 (m, 1H), 7.16 (ddd, J = 8.0, 7.5, 1.7 Hz, 1H), 3.48 (s, 3H), 1.57 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 133.4, 132.5, 129.5, 127.0, 125.8, 125.1, 96.0, 83.0, 71.2, 52.1, 28.4. IR (film) \tilde{v} 2983, 1467, 1433, 1360, 1289, 1266, 1186, 1171, 1146, 1072, 870, 794, 750, 679, 520 cm⁻¹. HRMS (GC-EI) for C₁₂H₁₃OBr [M]⁺: calcd. 252.01453; found: 252.01444.


2-Ethynyl-2-methoxyadamantane (S9)



Prepared analogously from 2-ethynyladamantan-2-ol 12 as a colorless oil (169 mg, 72%). 1 H NMR (400 MHz, CDCl $_{3}$) δ 3.37 (s, 3H), 2.52 (s, 1H), 2.16 – 2.09 (m, 2H), 2.08 – 2.02 (m, 4H), 1.88 – 1.75 (m, 4H), 1.71 – 1.67 (m, 2H), 1.57 – 1.48 (m, 2H). 13 C NMR (101 MHz, CDCl $_{3}$) δ 85.4, 77.9, 74.4, 50.1, 37.7, 35.5, 35.1, 31.5, 27.2,

26.7. IR (film) \tilde{v} 3304, 2900, 2848, 2104, 1450, 1228, 616, 511 cm⁻¹. HRMS (GC-EI) for C₁₃H₁₈O [M]⁺: calcd. 190.13516; found: 190.13522.


Mestranol methyl ether (S10)



Prepared analogously from commercially available mestranol as a colorless oil (266 mg, 55%). 1 H NMR (400 MHz, CDCl₃) δ 7.21 (dd, J = 8.7, 1.1 Hz, 1H), 6.71 (dd, J = 8.6, 2.8 Hz, 1H), 6.63 (d, J = 2.5 Hz, 1H), 3.78 (s, 3H), 3.42 (s, 3H), 2.95 – 2.77 (m, 2H), 2.61 (s, 1H), 2.44 – 2.17 (m, 3H), 2.01 (tt, J = 13.6, 4.9 Hz, 2H), 1.90 – 1.66 (m, 3H),


1.55 (s, 2H), 1.51 – 1.27 (m, 3H), 0.88 (d, J = 0.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 157.5, 138.0, 132.7, 126.5, 113.9, 111.6, 85.8, 84.8, 75.8, 55.3, 53.4, 49.6, 47.6, 43.6, 39.3, 36.7, 34.2, 30.0, 27.4, 26.7, 22.8, 12.8. IR (film) \tilde{v} 2933, 1612, 1504, 1465, 1447, 1290, 1252, 1240, 1134, 1109, 1021, 904, 833 cm⁻¹. HRMS (GC-EI) for $C_{22}H_{28}O_2$ [M]⁺: calcd. 324.20838; found: 324.20849.

(E)-1-Methoxy-1-(oct-6-en-1-yn-1-yl)cyclohexane (1b)



Prepared according to a literature procedure. ¹³ The analytical data matched those previously reported.


(*E*)-1-(But-2-en-1-yl)-2-(3-methoxy-3-methylbut-1-yn-1-yl)benzene (S11)



n-BuLi (1.55 M in hexanes, 1.91 mL, 2.96 mmol) was added to a solution of **S8** (500 mg, 1.97 mmol) in THF (10 mL) at −78 °C. The mixture stirred for 20 min before TMEDA (0.29 mL, 1.97 mmol) was added. After stirring at −78 °C

for another 20 min, crotyl bromide (mixture of (E/Z)-isomers, 0.30 mL, 2.96 mmol) was introduced and stirring was continued for 15 h. Water (20 mL) was added and the mixture was extracted with *tert*-butyl methyl ether (3 x 20 mL). The combined organic fractions were dried over Na₂SO₄ and concentrated under reduced pressure. The purification of the residue was achieved by flash chromatography (silica, pentane/*tert*-butyl methyl ether 100:1) to yield the title compound as a colorless oil (mixture of isomers, 420 mg, 93%). ¹H NMR (400 MHz, CDCl₃) δ 7.41 (m, 1H), 7.28 – 7.22 (m, 1H), 7.20 (m, 1H), 7.14 (m, 1H), 5.68 – 5.44 (m, 2H), 3.58 – 3.47 (m, 2H), 3.45 (m, 3H), 1.75 – 1.66 (m, 3H), 1.56 (m, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 143.0, 132.4, 129.1, 128.7, 128.5, 126.7, 125.9, 122.3, 83.1, 71.2, 51.9, 37.7, 28.6, 18.0. IR (film) \tilde{v} 2983, 2934, 1483, 1447, 1377, 1359, 1279, 1171, 1146, 1074, 966, 755 cm⁻¹. HRMS (GC-Cl) for C₁₆H₂₁O [M+H]⁺: calcd. 229.15847; found: 229.15869.


(E)-Oct-6-en-1-yn-1-ylbenzene (S12a)



Prepared analogously from commercially available phenyl acetylene and bromide **S5** as a colorless oil (266 mg, 74%). ¹H NMR (400 MHz, CDCl₃) δ 7.40 (dt, J = 6.9, 1.8 Hz, 2H), 7.27 (ddd, J = 6.3, 2.6, 1.0

Hz, 3H), 5.57 – 5.37 (m, 2H), 2.40 (td, J = 7.1, 1.1 Hz, 2H), 2.15 (dtd, J = 7.6, 5.8, 1.4 Hz, 2H), 1.72 – 1.62 (m, 5H). ¹³C NMR (101 MHz, CDCl₃) δ 131.6, 130.4, 128.3, 127.6, 125.8, 124.2, 90.3, 80.8, 31.8, 28.7, 18.9, 18.1. IR (film) \tilde{v} 2934, 1598, 1490, 1441, 1330, 1070, 1027, 965, 912, 754, 690, 525 cm⁻¹. HRMS (GC-EI) for C₁₄H₁₆ [M]⁺: calcd. 184.12461; found: 184.12465.


(*E*)-1-methyl-4-(oct-6-en-1-yn-1-yl)benzene (S12b)



Prepared analogously from commercially available 1-ethynyl-4-methylbenzene and bromide $\bf S5$ as a slightly yellow oil (318 mg, 80%). 1 H NMR (400 MHz, CDCl₃) δ 7.31 – 7.27 (m, 2H), 7.11 –

7.06 (m, 2H), 5.55 - 5.38 (m, 2H), 2.39 (t, J = 7.2 Hz, 2H), 2.33 (s, 3H), 2.18 - 2.10 (m, 2H), 1.70 - 1.62 (m, 5H). ¹³C NMR (101 MHz, CDCl₃) δ 137.6, 131.5, 130.5, 129.1, 121.1, 89.5, 80.9, 31.8, 28.8, 21.5, 19.0, 18.1. IR (film) 2932, 2857, 1509, 1452, 1437, 965, 815, 526, 412 cm⁻¹.


(*E*)-1-methoxy-4-(oct-6-en-1-yn-1-yl)benzene (S12c)



Prepared analogously from commercially available 1-ethynyl-4-methoxybenzene and bromide **S5** as a slightly yellow oil (468 mg, 96%). 1 H NMR (400 MHz, CDCl₃) δ 7.36 – 7.30 (m, 2H),

6.84 - 6.78 (m, 2H), 5.55 - 5.38 (m, 2H), 3.80 (s, 3H), 2.38 (t, J = 7.2 Hz, 2H), 2.19 - 2.09 (m, 2H), 1.72 - 1.61 (m, 5H). ¹³C NMR (101 MHz, CDCl₃) δ 159.1, 133.0, 130.6, 125.8, 116.4, 113.9, 88.7, 80.6, 55.4, 31.8, 28.8, 18.9, 18.1. IR (film) 2933, 2836, 1606, 1508, 1288, 1243, 1171, 1034, 965, 829, 534 cm⁻¹. HRMS (ESI⁺) for $C_{15}H_{18}O$ [M+H]⁺: calcd. 215.14304, found: 215.14288.

(Z)-1-Chloro-4-(oct-6-en-1-yn-1-yl)benzene (S12d)




Prepared analogously from commercially available 1-ethynyl-4-methylbenzene and (Z)-6-bromohex-2-ene¹⁴ as a slightly yellow oil (297 mg, 63%). ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.28 (m, 2H), 7.27 – 7.22 (m, 2H), 5.51 (ddddd, J = 9.4, 7.9, 6.5, 4.7, 3.3 Hz, 1H),

5.44 – 5.35 (m, 1H), 2.41 (t, J = 7.1 Hz, 2H), 2.21 (qt, J = 7.2, 1.2 Hz, 2H), 1.71 – 1.62 (m, 5H). ¹³C NMR (101 MHz, CDCl₃) δ 133.6, 132.9, 129.6, 128.6, 125.1, 122.7, 91.4, 79.8, 28.6, 26.1,

19.0, 13.0. IR (film) 3013, 2933, 2861, 1488, 1454, 1397, 1345, 1090, 1014, 825, 699, 524 cm⁻¹. HRMS (GC-EI) for $C_{14}H_{15}CI$ [M]⁺: calcd. 218.08568, found: 218.08575.


(E)-Triisopropyl(oct-6-en-1-yn-1-yl)silane (S13)



Prepared analogously from commercially available TIPS-acetylene and bromide **S5** as a colorless oil (351 mg, 81%). ¹H NMR (400 MHz, CDCl₃) δ 5.51 – 5.35 (m, 2H), 2.24 (t, J = 7.0 Hz, 2H), 2.15 – 2.07 (m,

2H), 1.66 - 1.62 (m, 3H), 1.61 - 1.53 (m, 2H), 1.13 - 1.01 (m, 21H). ¹³C NMR (101 MHz, CDCl₃) δ 130.5, 125.8, 94.8, 80.3, 31.6, 28.9, 19.4, 18.7, 18.6, 11.4. IR (film) \tilde{v} 2941, 2892, 2864, 2171, 1462, 1017, 995, 964, 924, 882, 674, 619, 492 cm⁻¹. HRMS (GC-CI) for $C_{17}H_{33}Si$ [M]⁺: calcd. 265.23436; found: 265.23460.


1-((*E*)-Oct-6-en-1-yn-1-yl)adamantine (S14)



Prepared analogously from compounds **S4** and **S5** as a colorless oil (185 mg, 62%). 1 H NMR (400 MHz, CDCl₃) δ 5.51 – 5.34 (m, 2H), 2.14 (t, J = 7.1 Hz, 2H), 2.10 – 2.02 (m, 2H), 1.96 – 1.89 (m,

3H), 1.83 (d, J = 2.9 Hz, 6H), 1.71 – 1.62 (m, 8H), 1.56 – 1.47 (m, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 130.6, 125.3, 89.3, 78.6, 43.4, 36.4, 31.5, 29.4, 29.1, 28.1, 25.8, 18.1, 17.9. IR (film) \tilde{v} 2902, 2850, 1451, 1437, 1344, 1100, 964, 507 cm⁻¹. HRMS (GC-EI) for $C_{18}H_{26}$ [M]⁺: calcd. 242.20276; found: 242.20290.

2-Methoxy-2-((E)-oct-6-en-1-yn-1-yl)adamantine (S15)



Prepared analogously from alkyne **S9** and bromide **S5** as a colorless oil (231 mg, 96%). ¹H NMR (400 MHz, CDCl₃) δ 5.54 – 5.44 (m, 1H), 5.37 (tddd, J = 9.0, 7.3, 3.3, 1.6 Hz, 1H), 3.34 (s, 3H), 2.27 (t, J = 7.0 Hz, 2H), 2.22 – 1.98 (m, 8H), 1.81 (p, J = 3.2 Hz, 1H), 1.75 (dddd, J


= 11.4, 3.9, 2.6, 1.4 Hz, 3H), 1.68 (ddd, J = 4.3, 2.6, 1.6 Hz, 2H), 1.64 – 1.55 (m, 5H), 1.53 – 1.46 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 129.7, 124.8, 86.8, 81.8, 78.0, 49.8, 37.8, 35.9, 35.3, 31.7, 29.0, 27.4, 26.8, 26.1, 18.4, 12.9. IR (film) \tilde{v} 294, 2854, 1448, 1164, 1101, 1085, 877, 923, 699 cm⁻¹. HRMS (GC-EI) for C₁₉H₂₉O [M+H]⁺: calcd. 273.22129; found: 273.22129.

Mestranol derived enyne (S16)

Prepared analogously from alkyne **S10** and bromide **S5** as a colorless oil (212 mg, 83%). ¹H NMR (400 MHz, CDCl₃) δ 7.21 (dd, J = 8.6, 1.0 Hz, 1H), 6.71 (dd, J = 8.6, 2.8 Hz, 1H), 6.63 (d, J = 2.7 Hz, 1H), 5.54 – 5.44 (m, 1H), 5.39 (dddd, J = 10.8, 7.2, 4.3, 1.6 Hz, 1H), 3.78 (s, 3H), 3.40 (s, 3H), 2.92 – 2.80 (m, 2H),

2.31 (t, J = 7.0 Hz, 3H), 2.26 – 2.10 (m, 4H), 2.07 – 1.93 (m, 2H), 1.91 – 1.82 (m, 1H), 1.81 – 1.71 (m, 3H), 1.68 – 1.57 (m, 5H), 1.52 – 1.27 (m, 4H), 0.87 (d, J = 0.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 157.5, 138.1, 132.8, 129.7, 126.5, 124.8, 113.9, 111.6, 88.1, 81.0, 75.8, 55.3, 53.4, 53.2, 49.7, 47.6, 43.7, 39.3, 37.0, 34.4, 30.0, 29.0, 27.4, 26.7, 26.1, 22.8, 18.5, 12.9. IR (film) \tilde{v} 2933, 1496, 1453, 1255, 1238, 1102, 1086, 1039, 726, 694, 464 cm⁻¹. HRMS (GC-EI) for C₂₈H₃₈O₂ [M]⁺: calcd. 406.28702; found: 406.28663.


(E)-2-(Dec-8-en-3-yn-2-yloxy)tetrahydro-2H-pyran (S17)



Prepared analogously from 2-(but-3-yn-2-yloxy)tetrahydro-2*H*-pyran (mixture of diastereoisomers)¹⁵ and bromide **S5** as a colorless oil (mixture of diastereoisomers, 119 mg, 39%). ¹H NMR (400 MHz, CDCl₃) δ 5.52 – 5.32 (m, 2H), 5.00 – 4.72 (m, 1H), 4.59

-4.40 (m, 1H), 4.08 - 3.76 (m, 1H), 3.60 - 3.39 (m, 1H), 2.25 - 2.13 (m, 2H), 2.10 - 2.00 (m, 2H), 1.92 - 1.68 (m, 2H), 1.66 - 1.63 (m, 3H), 1.62 - 1.49 (m, 5H), 1.45 - 1.37 (m, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 130.4, 130.3, 125.7, 125.6, 96.8, 95.8, 85.0, 81.0, 80.0, 62.6, 62.5, 62.3, 61.1, 31.6, 31.6, 30.6, 28.5, 28.5, 25.5, 25.5, 22.6, 22.2, 19.6, 19.3, 18.2, 18.1, 17.9. IR (film) \tilde{v} 2937, 1440, 1335, 1116, 1073, 1019, 967, 873, 814 cm⁻¹. HRMS (GC-CI) for $C_{15}H_{24}O_2$ [M+H]⁺: calcd. 237.18491; found: 237.18459.

(E)-1-(1-Methoxycyclohexyl)oct-6-en-1-yn-3-ol (S18)



n-BuLi (1.55 M in hexanes, 4.67 mL, 7.24 mmol) was added dropwise to a solution of alkyne **S1** (1.00 g, 7.24 mmol) in THF (20 mL) at 0 °C. After stirring for 30 min, the mixture was cooled to –78 °C before a solution of (*E*)-hex-4-enal (923 mg, 9.41 mmol)¹⁶

in THF (10 mL) was added dropwise. After warming to room temperature, the solution was stirred overnight before the reaction was quenched with sat. aq. NH_4CI (10 mL), EtOAc (50 mL) and water (30 mL). The aqueous layer was extracted with EtOAc (3 × 50 mL) and the combined organic phases were washed with brine and dried over Na_2SO_4 . The solvent was removed under reduced pressure and the residue was purified by flash chromatography (silica, pentane/tert-butyl methyl


ether 3:1) to provide the title compound as colorless oil (1.01 g, 59%). ¹H NMR (400 MHz, CDCl₃) δ 5.56 – 5.35 (m, 2H), 4.44 (t, J = 6.5 Hz, 1H), 3.35 (s, 3H), 2.17 (tq, J = 7.5, 3.8, 3.1 Hz, 2H), 1.92 – 1.83 (m, 2H), 1.83 – 1.61 (m, 8H), 1.52 (dtd, J = 19.7, 12.3, 9.6 Hz, 5H), 1.38 – 1.20 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 130.2, 126.1, 87.1, 86.1, 74.0, 62.2, 50.8, 37.9, 36.9, 36.8, 28.5, 25.6, 22.9, 18.1. IR (film) \tilde{v} 2934, 2875, 1444, 1291, 1184, 1162, 1079, 1055, 1030, 965, 923, 734, 522 cm⁻¹. HRMS (ESI+) for C₁₅H₂₄O₂ [M+Na]+: calcd. 259.16685; found: 259.16677.

(E)-Oct-6-en-1-yne (S19)

Trimethylsilylacetylene (1.61 mL, 11.4 mmol) was dissolved in THF (50 mL) and the solution cooled to 0°C before *n*-BuLi (1.59 M in hexanes, 8.60 mL, 13.7 mmol) was added dropwise. After stirring for 30 min, a solution of bromide **S5** (3.00 g, 14.7 mmol) in DMPU (6.89 mL, 57.0 mmol) and THF (3 mL) was added dropwise. The mixture was stirred at ambient temperature overnight. Sat. aq. NH₄Cl (30 mL), *tert*-butyl methyl ether (100 mL) and water (50 mL) were introduced, the aqueous layer was extracted with *tert*-butyl methyl ether (3 x 75 mL) and the combined organic phases were washed with brine and dried over Na₂SO₄. The residue was filtered through a short plug of silica, eluting with pentane/*tert*-butyl methyl ether (20:1, 100 mL). All volatile compounds were removed under reduced pressure and the residue was directly used in the next step without further purification.

 K_2CO_3 (764 mg, 5.47 mmol) was added in one portion to a solution of the crude silyl alkyne (900 mg, 4.99 mmol) in MeOH (50 mL). After stirring overnight, water (20 mL) was added and the mixture was extracted with pentane (3 × 20 mL). Purification by distillation of the combined organic phases at atmospheric pressure provided the title compound as colorless oil (369 mg, 68%). ¹H NMR (400 MHz, CDCl₃) δ 5.52 – 5.34 (m, 2H), 2.18 (td, J = 7.2, 2.7 Hz, 2H), 2.08 (dtt, J = 7.6, 6.5, 1.2 Hz, 2H), 1.94 (t, J = 2.7 Hz, 1H), 1.67 – 1.62 (m, 3H), 1.58 (dt, J = 14.3, 7.2 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 130.3, 126.0, 84.7, 68.4, 31.6, 28.5, 18.1, 17.9. IR (film) \tilde{v} 2956, 2748, 2379, 1439, 1355, 921, 802 cm⁻¹. HRMS (ESI⁺) for C₈H₁₃ [M+H]⁺: calcd. 109.10110; found: 109.10118.

(E)-(2-Methoxydec-8-en-3-yn-2-yl)benzene (S20)



n-BuLi (1.59 M in hexanes, 330 μL, 525 μmol) was added dropwise to a solution of **S19** (73.3 mg, 573 μmol) in THF (2 mL) at 0°C. After stirring for 30 min, the mixture was cooled to -78 °C and a solution of acetophenone (43.4 μL, 372 μmol) in THF (0.5 mL) was

added. After stirring at -78 °C for 90 min, the mixture was stirred overnight at ambient

temperature. Water (10 mL) was introduced and the mixture was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue purified by flash chromatography (silica, pentane/*tert*-butyl methyl ether 3:1) to provide an inseparable mixture of the desired alcohol and remaining starting material.

A solution of this crude material (42.3 mg, 185 µmol) in THF (0.5 mL) was added dropwise to a suspension of NaH (13.3 mg, 556 µmol) in THF (1 mL) at 0 °C. After warming to ambient temperature, the mixture was stirred for additional 15 min, before it was cooled to 0 °C and methyl iodide (60 µL, 964 µmol) was added. The mixture was stirred overnight at ambient temperature before the reaction was quenched with water (10 mL) and *tert*-butyl methyl ether (20 mL). The aqueous layer was extracted with *tert*-butyl methyl ether (3 × 20 mL), the combined organic phases were washed with brine and dried over Na₂SO₄, the solvent was removed under reduced pressure and the residue was purified by flash chromatography (silica, pentane/*tert*-butyl methyl ether 15:1) to provide the title compound as colorless oil (37 mg, 82%). ¹H NMR (400 MHz, CDCl₃) δ 7.63 – 7.57 (m, 2H), 7.39 – 7.32 (m, 2H), 7.31 – 7.25 (m, 1H), 5.57 – 5.35 (m, 2H), 3.19 (s, 3H), 2.34 (t, J = 7.1 Hz, 2H), 2.14 (dtd, J = 7.7, 6.2, 1.4 Hz, 2H), 1.69 (s, 3H), 1.68 – 1.62 (m, 5H). ¹³C NMR (101 MHz, CDCl₃) δ 143.4, 130.4, 128.3, 127.7, 126.3, 126.0, 88.1, 80.3, 76.7, 52.4, 33.1, 31.9, 28.8, 18.3, 18.1. IR (film) \tilde{v} 2985, 2933, 1446, 1366, 1234, 1178, 1097, 975, 763, 699, 608 cm⁻¹. HRMS (ESl⁺) for C₁₇H₂₂O [M+Na]⁺: calcd. 265.15628; found: 265.15624.

(E)-1-Chloro-4-(2-methoxydec-8-en-3-yn-2-yl)benzene (S21)

Prepared analogously from 1-(4-chlorophenyl)ethan-1-one as a colorless oil (205 mg, 79%). 1 H NMR (400 MHz, CDCl₃) δ 7.56 – 7.49 (m, 2H), 7.34 – 7.29 (m, 2H), 5.61 – 5.32 (m, 2H), 3.18 (s, 3H), 2.33 (t, J = 7.1 Hz, 2H), 2.18 – 2.09 (m, 2H), 1.69


-1.60 (m, 8H). ¹³C NMR (101 MHz, CDCl₃) δ 142.1, 133.5, 130.3, 128.4, 127.7, 126.0, 88.5, 79.9, 76.3, 52.4, 33.0, 31.9, 28.8, 18.3, 18.1. IR (film) \tilde{v} 2988, 2934, 1488, 1451, 1232, 1001, 1014, 965, 866, 827, 606 cm⁻¹. HRMS (ESI⁺) for C₁₇H₂₁CIO [M+Na]⁺: calcd. 299.11731; found: 299.11693.

(E)-1-(2-Methoxydec-8-en-3-yn-2-yl)-4-(trifluoromethyl)benzene (S22)

Prepared analogously from 1-(4-(trifluoromethyl)phenyl)-ethan-1-one as colorless oil (335 mg, 87%). 1 H NMR (400 MHz, CDCl₃ δ 7.75 – 7.67 (m, 2H), 7.65 – 7.57 (m, 2H), 5.56 – 5.34 (m, 2H), 3.21 (s, 3H), 2.34 (t, J = 7.1 Hz, 2H), 2.19 –

2.08 (m, 2H), 1.70 – 1.61 (m, 8H). ¹³C NMR (101 MHz, CDCl₃) δ 147.7, 130.3, 129.9 (q, J = 32.1 Hz), 126.6, 126.1, 125.3 (q, J = 3.8 Hz), 123.0, 88.9, 79.6, 76.4, 52.6, 33.0, 31.9, 28.7, 18.3, 18.1. ¹⁹F NMR (282 MHz, CDCl₃) δ –62.5. IR (film) \tilde{v} 2936, 1619, 1409, 1323, 1163, 1124, 1097, 1078, 1066, 968, 622 cm⁻¹. HRMS (ESI+) for C₁₈H₂₁F₃O [M+Na]+: calcd. 333.14367; found: 333.14350.


Methyl (E)-4-(2-methoxydec-8-en-3-yn-2-yl)benzoate (S23)



Prepared analogously from methyl 4-acetylbenzoate as colorless oil (66.5 mg, 36%). ¹H NMR (400 MHz, CDCl₃) δ 8.06 – 7.98 (m, 2H), 7.73 – 7.58 (m, 2H), 5.53 – 5.36 (m, 2H), 3.92 (s, 3H), 3.20 (s, 3H), 2.34 (t, J = 7.1 Hz, 2H),

2.21 - 2.08 (m, 2H), 1.70 - 1.61 (m, 8H). ¹³C NMR (101 MHz, CDCl₃) δ 167.1, 148.8, 130.3, 129.7, 129.6, 126.3, 126.0, 88.7, 79.7, 76.6, 52.6, 52.3, 32.9, 31.9, 28.7, 18.3, 18.1. IR (film) 2989, 2935, 1722, 1610, 1435, 1274, 1234, 1094, 965, 773, 708 cm⁻¹. HRMS (ESI+) for $C_{19}H_{24}O_3$ [M+Na]+: calcd. 323.16176; found: 323.16216.


(E)-Oct-6-en-1-yn-1-ylferrocene (S24)



n-BuLi (1.57 M in hexanes, 906 μ L, 1.42 mmol) was added dropwise to a solution of ethynylferrocene (249 mg, 1.19 mmol) in THF (5 mL) at 0 °C. The mixture was stirred at this temperature for 20 min before

a solution of bromide **S5** (232 mg, 1.42 mmol) in DMPU (716 μ L) and THF (3 mL) was added dropwise. After stirring overnight at ambient temperature, the reaction was quenched with sat. aq. NH₄Cl (2 mL), *tert*-butyl methyl ether (10 mL) and water (2 mL). The aqueous layer was extracted with *tert*-butyl methyl ether (3 × 20 mL) and the combined organic phases were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue purified by flash chromatography (silica, pentane/*tert*-butyl methyl ether 50:1) to provide the title compound as orange oil (254 mg, 73%). ¹H NMR (400 MHz, C₆D₆) δ 5.52 – 5.23 (m, 2H), 4.40 (s, 2H), 4.10 (s, 5H), 3.89 (s, 2H), 2.21 (t, J = 7.1 Hz, 2H), 2.12 – 2.05 (m, 2H), 1.65 – 1.49 (m, 5H). ¹³C NMR (101 MHz, C₆D₆) δ 130.8, 125.8, 86.4, 79.2, 71.6, 70.1, 68.5, 67.4, 32.0, 29.2, 19.3, 18.0. IR (film) \tilde{v} 3096, 2931, 2856, 1452, 1436, 1412, 1326, 1257, 1106, 1001, 965, 817, 488 cm⁻¹. HRMS (ESI⁺) for C₁₈H₂₀Fe [M]⁺: calcd. 292.09089; found: 292.09091.


(E)-1-Methoxy-1-(non-7-en-1-yn-1-yl)cyclohexane (S25)



n-BuLi (1.55 M in hexanes, 390 μ L, 605 μ mol) was added dropwise to a solution of alkyne **S1** (83.7 mg, 606 μ mol) in THF (2 mL) at 0 °C. The mixture was stirred at this temperature for

30 min before a solution of bromide **S6** (123 mg, 696 μmol) in DMPU (300 μL) and THF (1.7 mL) was added dropwise. After warming to ambient temperature, the mixture was stirred overnight. Sat. aq. NH₄Cl (2 mL), *tert*-butyl methyl ether (20 mL) and water (10 mL) were added, the aqueous layer was extracted with *tert*-butyl methyl ether (3 × 20 mL) and the combined organic phases were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (silica, pentane/*tert*-butyl methyl ether 30:1) to provide the title compound as colorless oil (109 mg, 77%). ¹H NMR (400 MHz, CDCl₃) δ 5.60 – 5.25 (m, 2H), 3.35 (s, 3H), 2.23 (t, J = 6.8 Hz, 2H), 1.99 (tdt, J = 6.7, 5.3, 1.6 Hz, 2H), 1.92 – 1.77 (m, 2H), 1.66 – 1.62 (m, 5H), 1.55 – 1.41 (m, 9H), 1.34 – 1.12 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 131.1, 124.9, 86.3, 81.0, 74.0, 37.0, 32.0, 28.7, 28.3, 25.5, 22.9, 18.5, 17.9. IR (film) \tilde{v} 2932, 2856, 1447, 1292, 1184, 1092, 1081, 965, 925, 906 cm⁻¹. HRMS (GC-CI) for C₁₆H₂₆O [M+H]⁺: calcd. 235.20564; found: 235.20532.


(E)-1-(Methoxymethoxy)-1-(non-7-en-1-yn-1-yl)cyclohexane (S26)



Prepared analogously from alkyne **S2** and bromide **S6** as a colorless oil (109 mg, 82%). ¹H NMR (400 MHz, CDCl₃) δ 5.48 – 5.35 (m, 2H), 4.93 (s, 2H), 3.39 (s, 3H), 2.23 (t, J = 6.9 Hz,

2H), 2.04 - 1.95 (m, 2H), 1.91 (dt, J = 11.0, 3.7 Hz, 2H), 1.75 - 1.41 (m, 14H), 1.37 - 1.18 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 131.2, 125.1, 92.8, 87.4, 80.9, 75.4, 55.8, 39.1, 32.1, 28.8, 28.3, 25.5, 23.3, 18.7, 18.0. IR (film) \tilde{v} 2931, 2857, 1448, 1294, 1177, 1149, 1097, 1068, 1026, 965 cm⁻¹. HRMS (ESI⁺) for C₁₇H₂₈O₂ [M+Na]⁺: calcd. 287.19815; found: 287.19781.

1-(4-(But-2-en-1-yloxy)but-1-yn-1-yl)-1-methoxycyclohexane (S27)



NaH (98.8 mg, 4.12 mmol) was added in portions to a solution of 4-(1-methoxycyclohexyl)but-3-yn-1-ol (500 mg, 2.74 mmol)¹⁷ in DMF (14 mL) at 0 °C and the resulting suspension was stirred

for 30 min. Crotyl bromide (mixture of (E/Z)-isomers, 423 µL, 4.12 mmol). was added and stirring continued at ambient temperature overnight. Water (20 mL) was introduced and the mixture was extracted with *tert*-butyl methyl ether (3 × 50 mL). The combined organic phases were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue purified by flash chromatography (silica, pentane/*tert*-butyl methyl ether 25:1) to provide the title compound as colorless oil (mixture of (E/Z)-isomers, 453 mg, 70%). ¹H NMR (400 MHz, CDCl₃) δ 5.78 – 5.61 (m, 1H), 5.56 (dddd, J= 15.2, 7.9, 4.6, 1.6 Hz, 1H), 4.19 – 3.85 (m, 2H), 3.66 – 3.45 (m, 2H), 3.33 (s, 3H), 2.58 – 2.45 (m, 2H), 1.95 – 1.78 (m, 2H), 1.76 – 1.41 (m, 10H), 1.26 (tt, J= 9.4, 4.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 129.8, 128.1, 127.5, 126.8, 83.1, 82.2, 74.1,

71.7, 68.9, 68.6, 66.3, 50.6, 37.0, 25.7, 23.0, 20.3, 17.9, 13.3. IR (film) \tilde{v} 2933, 2856, 1447, 1293, 1184, 1135, 1092, 1086, 1027, 966, 925, 819 cm⁻¹. HRMS (ESI⁺) for C₁₅H₂₄O₂ [M+Na]⁺: calcd. 259.16685; found: 259.16676.

Dimethyl (E)-2-(but-2-en-1-yl)-2-(4-(1-hydroxycyclohexyl)but-3-yn-1-yl)malonate (S28)

A solution of LiHMDS (674 mg, 4.03 mmol) in THF (4 mL) was added dropwise at -78 °C to a solution of dimethyl (*E*)-2-(but-2-en-1-yl)-2-(but-3-yn-1-yl)malonate (mixture of (*E/Z*)-isomers, 800 mg, 3.36 mmol)¹⁸ in THF (30 mL). After stirring for 30 min

at this temperature, cyclohexanone (522 µL, 5.04 mmol) was added dropwise and the mixture was warmed to ambient temperature. The reaction was quenched with sat. aq. NH₄Cl (2 mL), EtOAc (50 mL) and water (20 mL), the aqueous phase was extracted with EtOAc (3 × 50 mL) and the combined organic layers were dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue purified by flash chromatography (silica, pentane/*tert*-butyl methyl ether 15:1-10:1-3:1) to provide the title compound as colorless oil (mixture of (*E/Z*)-isomers, 439 mg, 39%). ¹H NMR (400 MHz, CDCl₃) δ 5.68 – 5.48 (m, 1H), 5.25 (dddd, J = 16.5, 8.9, 4.4, 2.1 Hz, 1H), 3.72 (s, 6H), 2.73 – 2.54 (m, 2H), 2.25 – 2.07 (m, 4H), 1.87 – 1.77 (m, 3H), 1.71 – 1.59 (m, 5H), 1.59 – 1.44 (m, 5H), 1.33 – 1.17 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 171.6, 130.2, 128.4, 124.4, 123.4, 84.6, 83.2, 68.8, 57.5, 57.2, 52.7, 52.6, 40.3, 36.2, 31.8, 31.8, 30.3, 25.4, 23.5, 18.2, 14.4, 14.3, 13.0. IR (film) \tilde{v} 2933, 1720, 1444, 1270, 1236, 1199, 1178, 1132, 1066, 964, 904 cm⁻¹. HRMS (ESI⁺) for C₁₉H₂₈O₅ [M+Na]⁺: calcd. 359.18289; found: 359.18247.


Dimethyl (E)-2-(but-2-en-1-yl)-2-(4-(1-methoxycyclohexyl)but-3-yn-1-yl)malonate (S29)

A solution of **S28** (mixture of (E/Z)-isomers, 389 mg, 1.16 mmol) in THF (2 mL) was added dropwise to a suspension of NaH (85.1 mg, 3.55 mmol) in THF (4.5 mL) at 0 °C. After 5 min, the mixture was warmed to ambient temperature and

stirred for additional 10 min. It was then cooled to 0°C before MeI (370 μ L, 5.95 mmol) was added dropwise. The mixture was stirred at ambient temperature overnight. Water (20 mL) was introduced and the aqueous layer was extracted with *tert*-butyl methyl ether (3 × 50 mL). The combined organic phases were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue purified by flash chromatography (silica, pentane/*tert*-butyl methyl ether 20:1) to provide the title compound as colorless oil (mixture of (*E/Z*)-isomers, 318 mg, 79%). ¹H NMR (400 MHz, CDCl₃) δ 5.69 – 5.46 (m, 1H), 5.26 (ddddt, J = 14.7, 7.5, 5.6, 3.9, 1.9 Hz, 1H), 3.72 (s, 6H), 3.33 (s, 3H), 2.76 – 2.52 (m, 2H), 2.26 – 2.06 (m,

4H), 1.91 - 1.77 (m, 2H), 1.68 - 1.43 (m, 10H), 1.35 - 1.23 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 171.5, 171.5, 130.2, 128.4, 124.4, 123.4, 85.0, 81.7, 74.0, 57.6, 57.2, 52.6, 52.6, 50.6, 37.0, 36.3, 32.2, 32.1, 30.3, 25.7, 22.9, 18., 14., 14.3, 13.0. IR (film) \tilde{v} 3372, 2971, 2936, 1734, 1444, 1083, 1047, 969, 924, 880 cm⁻¹. HRMS (ESI⁺) for $C_{20}H_{30}O_5$ [M+Na]⁺: calcd. 373.19854; found: 373.19819.

(*E*)-*N*-(But-2-en-1-yl)-*N*-(4-(1-methoxycyclohexyl)but-3-yn-1-yl)-4-methylbenzenesulfonamide (S30)




N-(4-(1-Methoxycyclohexyl)but-3-yn-1-yl)-4-methylbenzenesul-fonamide (**S3**) (270 mg, 805 µmol) and K₂CO₃ (412 mg, 2.98 mmol) were suspended in MeCN (3 mL). Crotyl bromide (mixture of (E/Z)-isomers, 300 µL, 2.92 mmol) was added and

the mixture was stirred at 60 °C overnight. After cooling to room temperature, the mixture was filtered through a pad of cotton wool and the residue in the filter was washed with MeCN (15 mL). The combined filtrates was concentrated and the crude material was purified by flash chromatography (silica, pentane/*tert*-butyl methyl ether 10:1-3:1) to provide the title compound as colorless oil (mixture of (E/Z)-isomers, 269 mg, 86%). ¹H NMR (400 MHz, CDCl₃) δ 7.77 – 7.68 (m, 2H), 7.34 – 7.28 (m, 2H), 5.68 – 5.55 (m, 1H), 5.33 – 5.23 (m, 1H), 3.83 (ddt, J = 46.8, 6.6, 1.1 Hz, 2H), 3.31 (s, 3H), 3.30 – 3.24 (m, 2H), 2.57 – 2.46 (m, 2H), 2.43 (s, 3H), 1.88 – 1.77 (m, 2H), 1.71 – 1.43 (m, 10H), 1.35 – 1.22 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 143.3, 143.2, 137.2, 137.1, 130.6, 129.7, 129.7, 128.8, 127.1, 125.6, 124.8, 82.9, 82.6, 73.9, 50.5, 50.5, 46.5, 46.1, 44.8, 36.8, 25.5, 22.7, 21.5, 19.7, 19.6, 17.7, 12.9. IR (film) \tilde{v} 2935, 1449, 1341, 1202, 1157, 1081, 928, 816, 743, 655, 548 cm⁻¹. HRMS (ESI⁺) for C₂₂H₃₁NO₃S [M+H]⁺: calcd. 412.19169; found: 412.19197.

3.2 Synthesis of the Precatalysts

Since preliminary results showed that the purity of the catalyst has a significant impact on the outcome of the catalytic transformation, a modified and optimized synthesis procedure for [(IPr)(cymene)RuCl₂] was developed. In our hands, literature protocols for the synthesis of this complex did not provide material of acceptable quality.¹⁹

[(IPr)(η⁶-cymene)RuCl₂] (3c)



[(*p*-Cymene)RuCl₂]₂ (487 mg, 795 μmol) was suspended in THF (15 mL) and a solution of IPr (607 mg, 1.55 mmol) in THF (15 mL) was added dropwise within 5 min. The resulting mixture was stirred for 1 h at ambient temperature in the dark. All volatile components were removed under high vacuum. The residue was redissolved in a minimum amount of CH₂Cl₂ and the turbid solution was filtered through a pad of neutral aluminium

oxide. Eluting with $CH_2CI_2/MeOH$ (50:1, 50 mL) provided an orange solution, which was concentrated under high vacuum. The residue was redissolved in a minimum amount of benzene and filtered through a short pad of Celite, which was eluted with benzene (80 mL). The orange solution was concentrated under high vacuum until the product started to precipitate. At this point, the solution was cooled to 0 °C before pentane (150 mL) was added until an orange solid precipitated from the mixture. The supernatant was siphoned off and the resulting solid was washed with pentane (2 × 25 mL) and dried under high vacuum. The title compound was obtained as orange solid (715 mg, 66%). ¹H NMR (400 MHz, C_6D_6) δ 7.24 (dd, J = 8.4, 7.0 Hz, 2H), 7.15 – 7.11 (m, 4H), 6.49 (s, 2H), 4.86 (d, J = 5.8 Hz, 2H), 4.52 (d, J = 5.8 Hz, 2H), 3.38 (hept, J = 6.7 Hz, 4H), 2.65 (hept, J = 6.8 Hz, 1H), 1.77 (s, 3H), 1.49 (d, J = 6.7 Hz, 12H), 1.07 (d, J = 7.0 Hz, 6H), 1.02 (d, J = 6.8 Hz, 12H). 13 C NMR (101 MHz, C_6D_6) δ 173.7, 146.4, 140.2, 129.8, 126.5, 123.8, 105.4, 96.9, 86.5, 84.3, 30.4, 28.9, 26.4, 23.5, 22.9, 18.8. The spectroscopic data are consistent with those reported in the literature. 19

During this study, the authors used several batches of 3c and did not notice any significant decomposition or change in the catalytic performance when the material was stored in the dark at -20 °C.

Complexes of the type [(NHC)(p-cymene)RuCl₂] are moderately light-sensitive in solution. Solutions of such complexes should therefore be handled in the dark; the light of the fume-hood should be switched off during any manipulations.

[(IMes)(η^6 -cymene)RuCl₂] (3b). Prepared analogously; the spectroscopic data are consistent with those reported in the literature.¹⁹

4. Hydrogenative Metathesis Reactions

General Procedure: Intramolecular Hydrogenative Enyne Metathesis

A flame-dried quartz Schlenk tube was charged with [(IPr)(*p*-cymene)RuCl₂] (13.8 mg, 0.02 mmol, 10 mol%), the substrate (0.2 mmol) and toluene (2 mL, 0.1 M). The Schlenk tube was closed with a septum and then transferred into the photolysis apparatus. A hydrogen-filled balloon was connected to a needle which was pierced through the septum and the Schlenk tube was flushed with hydrogen for 2 min through an outlet cannula (the cannula did not reach into the solution to make sure that only the head space of the tube was flushed). After the first 10 seconds of flushing with hydrogen, the light source was switched on and the reaction mixture was stirred for 60 min under hydrogen atmosphere. The reaction mixture was diluted with pentane (5 mL) and then filtered through a short pad of silica. The filtrate was evaporated and the residue purified by flash chromatography.

1-(Cyclopent-1-en-1-ylmethyl)-1-methoxycyclohexane (2)

Prepared according to the General Procedure from enyne 1b (44.1 mg, 200 µmol); colorless oil (36.9 mg, 95%). When the reaction was carried out on a 1 mmol scale (220 mg of 1b), a yield of 88% (172 mg) was obtained.

When the same reaction was performed in ordinary laboratory glassware (instead of the quartz Schlenk-tube), a yield of 75% was obtained.


The analytical data of 2 matched those previously reported in the literature.^[21]

The following compounds were prepared analogously:

2-((1-Methoxycyclohexyl)methyl)cyclopent-2-en-1-ol (5)

Prepared from substrate **S18**; colorless oil (29.5 mg, 70%). ¹H NMR (400 MHz, CDCl₃) δ 5.60 (s, 1H), 4.57 – 4.49 (m, 1H), 4.06 (s, 1H), 3.25 (s, 3H), 2.59 – 2.43 (m, 1H), 2.42 – 2.30 (m, 2H), 2.25 – 2.06 (m, 2H), 1.91 – 1.65 (m, 4H), 1.61 – 1.22 (m, 7H). ¹³C NMR (101 MHz, CDCl₃) δ 141.9, 132.9, 78.4, 76.3, 48.2, 36.3, 34.4, 33.6, 33.5, 30.1, 25.8, 22.5, 22.1. IR (film) \tilde{v} 3423, 2930, 2853, 1456, 1146, 1131, 1079, 951 cm⁻¹. HRMS (ESI⁺) for C₁₃H₂₂O₂ [M+Na]⁺: calcd. 233.15120; found: 233.15141.


2-(Cyclopent-1-en-1-ylmethyl)-2-methoxyadamantane (6)



Prepared from substrate **S15**; colorless oil (37.1 mg, 75%). ¹H NMR (400 MHz, CDCl₃) δ 5.44 (td, J = 2.3, 1.2 Hz, 1H), 3.19 (s, 3H), 2.51 (s, 2H), 2.41 – 2.24 (m, 4H), 2.11 (dd, J = 12.7, 3.2 Hz, 2H), 1.94 – 1.76 (m, 8H), 1.74 – 1.62 (m, 4H), 1.50 – 1.41 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 140.5, 127.3, 79.4, 47.2,

38.6, 36.6, 34.6, 34.0, 32.9, 32.4, 31.5, 27.8, 27.4, 23.8. IR (film) \tilde{v} 2905, 2852, 1455, 1115, 1083, 1061, 993 cm⁻¹. HRMS (ESI⁺) for C₁₇H₂₆ONa [M]⁺: calcd. 269.18767; found: 269.18758.


3-(2-Methoxy-2-methylpropyl)-1*H*-indene (7)



Prepared from substrate **S11**; colorless oil (27.0 mg, 66%). ¹H NMR (400 MHz, CDCl₃) δ 7.46 (dt, J = 7.4, 1.0 Hz, 1H), 7.42 (dt, J = 7.7, 0.9 Hz, 1H), 7.33 – 7.28 (m, 1H), 7.19 (td, J = 7.4, 1.2 Hz, 1H), 6.40 – 6.35 (m, 1H), 3.39 – 3.34 (m, 2H), 3.31 (s, 3H), 2.77 (d, J = 1.4 Hz, 2H), 1.24 (s, 6H). ¹³C NMR (101 MHz, CDCl₃)

 δ 146.4, 144.1, 140.7, 131.7, 126.0, 124.4, 123.7, 119.6, 75.5, 49.5, 38.1, 37.5, 25.3. IR (film) \tilde{v} 2972, 2937, 1717, 1462, 1383, 1366, 1241, 1161, 1070, 1020, 879, 764 cm⁻¹. HRMS (GC-EI) for $C_{14}H_{18}O$ [M]⁺: calcd. 202.13490; found: 202.13522.


(1-(Cyclopent-1-en-1-yl)-2-methoxypropan-2-yl)benzene (8a)



Prepared from substrate **\$20**; colorless oil (36.8 mg, 85%). 1 H NMR (400 MHz, CDCl₃) δ 7.40 – 7.23 (m, 4H), 7.23 – 7.09 (m, 1H), 5.27 – 5.22 (m, 1H), 3.00 (s, 3H), 2.60 – 2.43 (m, 2H), 2.23 – 2.11 (m, 2H), 2.06 – 1.94 (m, 1H),

1.83 - 1.49 (m, 3H), 1.47 (s, 3H). 13 C NMR (101 MHz, CDCl₃) δ 145.2, 140.7, 128.4, 128.0, 126.9, 126.5, 79.3, 50.4, 45.0, 36.4, 32.5, 23.9, 22.4. IR (film) \tilde{v} 2977, 2934, 2846, 2824, 1445, 1371, 1155, 1098, 1072, 764 cm⁻¹. HRMS (ESI+) for $C_{15}H_{21}O$ [M+Na]+: calcd. 217.15869; found: 217.15847.

1-Chloro-4-(1-(cyclopent-1-en-1-yl)-2-methoxypropan-2-yl)benzene (8b)



Prepared from substrate **S21**; colorless oil (42.0 mg, 85%). ¹H NMR (400 MHz, CDCl₃) δ 7.29 (s, 4H), 5.34 – 5.26 (m, 1H), 3.06 (s, 3H), 2.60 – 2.46 (m, 2H), 2.26 – 2.16 (m, 2H), 2.12 – 2.00 (m, 1H), 1.89 – 1.78 (m, 1H), 1.77 – 1.65 (m, 2H), 1.51 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 143.9,


140.3, 132.7, 128.8, 128.2, 128.0, 79.0, 50.5, 45.0, 36.5, 32.5, 24.0, 22.5. IR (film) \tilde{v} 2932, 1842, 1489, 1398, 1153, 1114, 1085, 1055, 1013, 829 cm⁻¹. HRMS (ESI⁺) for C₁₅H₁₉CIO [M+Na]⁺: calcd. 273.10166; found: 273.10150.

1-(1-(Cyclopent-1-en-1-yl)-2-methoxypropan-2-yl)-4-(trifluoromethyl)benzene (8c)

Prepared from substrate **S22**; colorless oil (48.0 mg, 85%). ¹H NMR (400 MHz, CDCl₃) δ 7.62 – 7.55 (m, 2H), 7.53 – 7.43 (m, 2H), 5.35 – 5.23 (m, 1H), 3.09 (s, 3H), 2.63 – 2.50 (m, 2H), 2.26 – 2.18 (m, 2H), 2.14 – 2.02 (m, 1H), 1.92 – 1.80 (m, 1H), 1.79 – 1.65 (m, 2H), 1.55 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 149.7, 140.1, 129.0, 126.8, 129.2 (q, J = 32.2 Hz), 125.1 (q, J = 3.7 Hz), 124.4 (q, J = 272.2 Hz), 79.2, 50.6, 44.8, 36.5, 32.5, 24.0, 22.6. ¹⁹F NMR (282 MHz, CDCl₃) δ –62.4. IR (film) \tilde{v} 2937, 1619, 1410, 1324, 1163, 1119, 1075, 1016, 844 cm⁻¹. HRMS (APPI⁺) for C₁₆H₁₉F₃O [M+Na]⁺: calcd. 284.13825; found: 284.13788.

Methyl 4-(1-(cyclopent-1-en-1-yl)-2-methoxypropan-2-yl)benzoate (8d)




211.16921.


Prepared from substrate **S23**; colorless oil (42.6 mg, 80%). 1 H NMR (400 MHz, CDCl₃) δ 8.04 – 7.94 (m, 2H), 7.49 – 7.41 (m, 2H), 5.37 – 5.21 (m, 1H), 3.91 (s, 3H), 3.08 (s, 3H), 2.64 – 2.49 (m, 2H), 2.27 – 2.13 (m, 2H), 2.09 – 1.96 (m, 1H), 1.86 – 1.75 (m, 1H), 1.75 – 1.61

(m, 2H), 1.55 (s, 3H). 13 C NMR (101 MHz, CDCl₃) δ 167.2, 150.8, 140.2, 129.5, 128.9, 128.8, 126.6, 79.4, 52.2, 50.6, 44.9, 36.5, 32.5, 24.0, 22.5. IR (film) \tilde{v} 2948, 1723, 1435, 1277, 1109, 1087, 1056, 775, 711 cm⁻¹. HRMS (GC-CI) for $C_{17}H_{22}O_3$ [M+H]⁺: calcd. 275.16417; found: 275.16440.

2-((1-(Cyclopent-1-en-1-yl)propan-2-yl)oxy)tetrahydro-2*H*-pyran (9)



Compound 10




Prepared from substrate **S16**; white solid (52.0 mg, 68%). 1 H NMR (400 MHz, CDCl₃) δ 7.20 (dd, J = 8.7, 1.1 Hz, 1H), 6.71 (dd, J = 8.6, 2.8 Hz, 1H), 6.63 (d, J = 2.7 Hz, 1H), 5.61 – 5.50 (m, 1H), 3.78 (s, 3H), 3.26 (s, 3H), 2.89 – 2.83 (m, 2H), 2.75 (d,

J = 15.9 Hz, 1H), 2.48 – 2.23 (m, 4H), 2.22 – 2.08 (m, 2H), 2.08 – 1.93 (m, 1H), 1.93 – 1.79 (m, 3H), 1.74 (td, J = 12.6, 4.0 Hz, 1H), 1.69 – 1.52 (m, 3H), 1.52 – 1.21 (m, 6H), 0.97 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 157.5, 140.8, 138.1, 132.8, 127.2, 126.3, 113.9, 111.6, 88.0, 55.3, 51.5, 50.9, 47.5, 43.7, 39.6, 36.7, 34.5, 34.0, 32.6, 31.8, 30.0, 27.5, 26.7, 23.6, 23.4, 13.9. IR (film) \tilde{v} 2933, 1504, 1245, 1158, 1093, 1081, 1063, 1036, 843, 451 cm⁻¹. HRMS (GC-EI) for C₂₆H₃₆O₂ [M+Na]⁺: calcd. 403.26099; found: 403.26075.

(Cyclopent-1-en-1-ylmethyl)triisopropylsilane (11)

Prepared from substrate **S13**; colorless oil (39.5 mg, 84%). ¹H NMR (400 MHz, CDCl₃) δ 5.22 (q, J = 1.5 Hz, 1H), 2.26 (t, J = 7.4 Hz, 4H), 1.82 (p, J = 7.4 Hz, 2H), 1.66 (s, 2H), 1.05 (s, 21H). ¹³C NMR (101 MHz, CDCl₃) δ 142.0, 122.6, 38.0, 32.6, 24.1, 18.8, 13.5, 11.6. IR (film) \tilde{v} 2940, 2891, 2865, 1463, 1015, 998, 882, 745, 663 cm⁻¹. HRMS (GC-EI) for C₁₅H₃₀Si [M]⁺: calcd. 238.21074; found: 238.21113.


1-(Cyclopent-1-en-1-ylmethyl)adamantine (12)



Prepared from substrate **S14**; colorless oil (42.1 mg, 95%). ¹H NMR (400 MHz, CDCl₃) δ 5.29 (tt, J = 2.1, 1.0 Hz, 1H), 2.34 – 2.22 (m, 4H), 1.96 – 1.90 (m, 3H), 1.88 – 1.79 (m, 4H), 1.73 – 1.58 (m, 6H), 1.48 (d, J = 2.8 Hz, 6H).

¹³C NMR (101 MHz, CDCl₃) δ 141.7, 127.2, 46.0, 43.0, 38.3, 37.2, 33.4, 32.6, 29.0, 24.3. IR (film) \tilde{v} 2896, 2844, 1449, 1345, 1315, 1101, 1036, 956, 820, 802, 467 cm⁻¹. HRMS (GC-EI) for C₁₆H₂₄ [M]⁺: calcd. 216.18734; found: 216.18725.


(Cyclopent-1-en-1-ylmethyl)ferrocene (13)



Prepared from substrate **S24**; orange oil (41.5 mg, 84%). The isolated product is only modestly stable and decomposes upon storage. 1 H NMR (400 MHz, CDCl₃) δ 5.26 – 5.22 (m, 1H), 4.10 (s, 5H), 4.07 (t, J = 1.8 Hz, 2H), 4.06 – 4.04 (m, 2H), 3.12 (q, J = 1.3 Hz, 4H), 2.31 – 2.17 (m, 2H). 13 C NMR (101 MHz,

CDCl₃) δ 144.5, 124.1, 68.7, 68.6, 67.2, 35.1, 32.3, 31.9, 23.4. IR (film) \tilde{v} 2922, 2843, 1105, 1038, 1022, 1009, 959, 814, 480 cm⁻¹. HRMS (EI) for C₁₆H₁₈Fe [M]⁺: calcd. 266.07579; found: 266.07570.


(Cyclopent-1-en-1-ylmethyl)benzene (14a) and 1-Phenylcyclohexene (14'a)



Prepared from substrate **S12a**; colorless oil (**14a**:**14'a** = 2:1, 21.0 mg, 66%). The analytical data of **14b** matched those reported in the literature, ²⁰ as well as those of a commercial sample. Spectral data of **14a**: ¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.37 (m, 2H), 7.35 – 7.27 (m, 2H), 7.23 – 7.17 (m, 1H), 5.38 – 5.31 (m, 1H), 3.40 (d, J = 2.2 Hz, 2H), 2.36 –

2.29 (m, 2H) 2.26 – 2.17 (m, 2H), 1.93 – 1.84 (m, 2H). 13 C NMR (101 MHz, CDCl₃) δ 143.9, 140.3, 128.9, 125.9, 125.6, 125.0, 38.1, 34.9, 32.5, 23.6. HRMS (GC-EI) for $C_{12}H_{15}$ [M+H]⁺: calcd. 159.11663; found: 159.11683.


1-(Cyclopent-1-en-1-ylmethyl)-4-methylbenzene (14b) and 4'-Methyl-2,3,4,5-tetrahydro-1,1'-biphenyl (14'b)



3.6, 1.8 Hz, 2H), 1.90 – 1.83 (m, 2H).

Prepared from substrate **S12b**; colorless oil (**14b**:**14'b** = 2:1, 27.0 mg, 78%). The analytical data of the compounds matched those reported in the literature.²¹ ¹H NMR (400 MHz, CDCl₃) δ 7.09 (d, J = 3.2 Hz, 4H), 5.34 (hept, J = 1.9 Hz, 1H), 3.36 (s, 2H), 2.33 (s, 3H), 2.31 – 2.28 (m, 2H), 2.20 (tdd, J = 7.1,


1-(Cyclopent-1-en-1-ylmethyl)-4-methoxybenzene (14c) and 4'-Methoxy-2,3,4,5-tetrahydro-1,1'-biphenyl (14'c)



Prepared from substrate **S12c**; colorless oil (**14c**:**14**'**c** = 2:1, 23.0 mg, 61%). The analytical data matched those reported in the literature.²² ¹H NMR (400 MHz, CDCl₃) δ 7.14 – 7.05 (m, 2H), 6.91 – 6.79 (m, 2H), 5.35 – 5.30 (m, J = 2.3 Hz, 1H), 3.79 (s, 3H), 3.33 (s, 2H), 2.31 (tp, J = 6.6, 2.2 Hz, 2H), 2.19 (tq,

J = 5.8, 1.9 Hz, 2H), 1.86 (tt, J = 8.2, 6.7 Hz, 2H).


1-Chloro-4-(cyclopent-1-en-1-ylmethyl)benzene (14d) and 4'-Chloro-2,3,4,5-tetrahydro-1,1'-biphenyl (14'd)



Prepared from substrate **S12d**; colorless oil (**14d**:**14'd** = 2:1, 31.7 mg, 41%; NMR yield with tetramethylbenzene as internal standard). In this case, flash chromatography did not allow trace amounts of by-products to be separated; however, the product structure could be confirmed by

comparison of the NMR data with those reported in the literature.²³ ¹H NMR (400 MHz, CDCl₃) (characteristic signals only): δ 7.26 – 7.24 (m, 2H), 7.13 – 7.09 (m, 2H), 5.35 – 5.32 (m, 1H), 3.35 (s, 2H), 2.35 – 2.28 (m, 2H), 2.24 – 2.15 (m, 2H), 1.92 – 1.82 (m, 2H).


1-((1-Methoxycyclohexyl)methyl)cyclohex-1-ene (15a)



Prepared from substrate **S25**; colorless oil (32.0 mg, 77%). 1 H NMR (400 MHz, CDCl₃) δ 5.44 – 5.34 (m, 1H), 3.17 (s, 3H), 2.08 – 1.94 (m, 5H), 1.73 – 1.63 (m, 2H), 1.62 – 1.36 (m, 9H), 1.33 – 1.15 (m, 4H). 13 C NMR (101 MHz,

CDCl₃) δ 134.6, 125.0, 75.8, 48.2, 44.1, 34.4, 30.3, 26.0, 25.6, 23.3, 22.4, 22.1. IR (film) \tilde{v} 2925, 2854, 1454, 1146, 1123, 1079, 917, 811, 707 cm⁻¹. HRMS (ESI+) for C₁₄H₂₄O [M+Na]+: calcd. 231.17193; found: 231.17224.


1-((1-(Methoxymethoxy)cyclohexyl)methyl)cyclohex-1-ene (15b)



Prepared from substrate **S26** using 20 mol% of catalyst; colorless oil (24.6 mg, 79%). 1 H NMR (400 MHz, CDCl₃) δ 5.44 – 5.37 (m, 1H), 4.73 (s, 2H), 3.41 (s, 3H), 2.18 – 2.10 (m, 2H), 2.03 – 1.98 (m, 4H), 1.75 – 1.67 (m,

2H), 1.65 - 1.50 (m, 5H), 1.48 - 1.36 (m, 5H), 1.33 - 1.19 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 134.4, 125.5, 90.7, 78.1, 55.8, 46.5, 35.4, 30.7, 25.8, 25.6, 23.3, 22.4. IR (film) \tilde{v} 2926, 2856, 1448, 1157, 1140, 1085, 1032, 922 cm⁻¹. HRMS (ESI+) for $C_{15}H_{26}O_2$ [M]+: calcd. 261.18250; found: 261.18268.

4-((1-Methoxycyclohexyl)methyl)-1-tosyl-1,2,3,6-tetrahydropyridine (16)




Prepared from substrate **S30**; colorless oil (49.0 mg, 75%). ¹H NMR (400 MHz, CDCl₃) δ 7.68 – 7.64 (m, 2H), 7.33 – 7.28 (m, 2H), 5.32 (tdd, J = 3.4, 1.7, 0.8 Hz, 1H), 3.56 (dt, J = 3.5, 1.3 Hz, 2H), 3.15 – 3.11 (m, 5H), 2.42

(s, 3H), 2.24 (tq, J = 4.6, 2.1 Hz, 2H), 2.06 (d, J = 1.5 Hz, 2H), 1.67 – 1.55 (m, 2H), 1.55 – 1.31

(m, 5H), 1.25 - 1.09 (m, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 143.5, 133.5, 133.4, 129.6, 127.8, 119.9, 75.6, 48.1, 45.0, 43.1, 42.6, 34.3, 29.9, 25.8, 21.9, 21.6. IR (film) \tilde{v} 2931, 1685, 1342, 1292, 1162, 1132, 1071, 949, 814, 708, 687, 644 cm⁻¹. HRMS (ESI+) for $C_{20}H_{29}NO_3S$ [M+Na]+: calcd. 386.17604; found: 386.17615.


4-((1-Methoxycyclohexyl)methyl)-3,6-dihydro-2*H*-pyran (17)



Prepared from substrate **S27**; colorless oil (31.6 mg, 76%). ¹H NMR (400 MHz, CDCl₃) δ 5.43 (tt, J = 2.9, 1.4 Hz, 1H), 4.13 (tt, J = 2.7, 1.4 Hz, 2H), 3.75 (t, J = 5.5 Hz, 2H), 3.18 (s, 3H), 2.20 – 2.15 (m, 2H), 2.12 (d, J = 1.6

Hz, 2H), 1.74 - 1.66 (m, 2H), 1.61 - 1.37 (m, 4H), 1.33 - 1.15 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 132.6, 123.6, 75.8, 65.7, 64.7, 48.2, 43.1, 34.5, 30.3, 26.0, 22.1. IR (film) 2932, 2854, 2826, 1725, 1456, 1166, 1135, 1080, 912, 732 cm⁻¹. HRMS (ESI+) for $C_{13}H_{22}O_2$ [M+Na]+: calcd. 233.15120; found: 233.15108.


Dimethyl 4-((1-methoxycyclohexyl)methyl)cyclohex-3-ene-1,1-dicarboxylate (18)





Prepared from substrate **S29** using 20 mol% of the catalyst; colorless oil (48.5 mg, 79%). 1 H NMR (400 MHz, CDCl₃) δ 5.39 – 5.33 (m, 1H), 3.69 (s, 6H), 3.13 (s, 3H), 2.63 – 2.45 (m, 2H), 2.11 (s,


4H), 2.04 (s, 2H), 1.64 – 1.56 (m, 2H), 1.55 – 1.33 (m, 4H), 1.27 – 1.13 (m, 4H). 13 C NMR (101 MHz, CDCl₃) δ 172.3, 134.1, 121.6, 75.8, 52.9, 52.7, 48.1, 43.1, 34.3, 31.1, 28.3, 26.9, 25.9, 22.0. IR (film) \tilde{v} 2932, 1731, 1434, 1253, 1072, 911, 729 cm⁻¹. HRMS (ESI+) for C₁₈H₂₈O₅ [M+Na]+: calcd. 347.18289; found: 347.18293.


5. Copies of Spectra





















































































































110 100 (ppm) 





































































































































































































6. References

- G. R. Fulmer, A. J. M. Miller, N. H. Sherden, H. E. Gottlieb, A. Nudelman, B. M. Stoltz, J. E. Bercaw, K. I. Goldberg, *Organometallics* **2010**, *29*, 2176–2179
- A. Fürstner, P. W. Davies, C. W. Lehmann, *Organometallics* **2005**, *24*, 4065-4071.
- ³ T. Ritter, A. Hejl, A. G. Wenzel, T. W. Funk, R. H. Grubbs, *Organometallics* **2006**, *25*, 5740-5745.
- J. Engel, W. Smit, M. Foscato, G. Occhipinti, K. W. Törnroos, V. R. Jensen, *J. Am. Chem. Soc* 2017, 139, 16609-16619.
- G. Bailey, M. Foscato, C. S. Higman, C. S. Day, V. R. Jensen, D. E. Fogg. *J. Am. Chem. Soc.* 2018, 140, 6931-6944.
- ⁶ A. Guthertz, M. Leutzsch, L. M. Wolf, P. Gupta, S. M. Rummelt, R. Goddard, C. Farès, W. Thiel, A. Fürstner, *J. Am. Chem. Soc.* **2018**, *140*, 3156-3169.
- The procedure follows the preparation of an analogous complex carrying a saturated H₂IMes ligand described in ref. 5
- S. Barlow, J.-L. Brédas, Y. A. Getmanenko, R. L. Gieseking, J. M. Hales, H. Kim, S. R. Marder, J. W. Perry, C. Risko, Y. Zhang, *Mater. Horiz.* **2014**, *1*, 577.
- 9 N. Z. Burns, M. R. Witten, E. N. Jacobsen, *J. Am. Chem. Soc.* **2011**, *133*, 14578-14581.
- ¹⁰ T. S. Ahmed, T. P. Montgomery, R. H. Grubbs, *Chem. Sci.* **2018**, *9*, 3580–3583.
- L. M. Bannwart, L. Jundt, T. Müntener, M. Neuburger, D. Häussinger, M. Mayor, *Eur. J. Org. Chem.* **2018**, 3391.
- C. Battilocchio, I. R., Baxendale, M. Biava, M. O. Kitching, S. V. Ley, *Org. Process Res. Dev.* **2012**, *16*, 798.
- ¹³ S. Peil, A. Guthertz, T. Biberger, *Angew. Chem. Int. Ed.* **2019**, *58*, 8851.
- ¹⁴ S. Nicolai, P. Swallow, J. Waser *Tetrahedron* **2015**, *71*, 5959-5964.
- G.C. Tsui, K. Villeneuve, E. Carlson, W. Tam, *Organometallics* **2014**, *33*, 3847-3856.
- ¹⁶ J.-S. Ryu, T. J. Marks, F. E. McDonald, *Org. Lett.* **2001**, 3, 3091-3094.
- ¹⁷ P. A. Allegretti, E. M. Ferreira, *Org. Lett.* **2011**, 13, 5924-5927.
- ¹⁸ B. M. Trost, F. D. Toste, *J. Am. Chem. Soc.* **2002**, *124*, 5025-5036.
- L. Jafarpour, J. Huang, E. D. Stevens, S. P. Nolan, *Organometallics* **1999**, *18*, 3760-3763.
- ²⁰ X. Wu, Y. Lu, H. Hirao, J. Zhou, *Chem. Eur. J.* **2013**, *19*, 6014-6020.
- a) Compound 14b: D.-H. Lee, K.-H. Kwon, C. S. Yi. Science 2011, 333, 1613-1616; b) compound 14'b: L. J. Rono, H. G. Yayla, D. Y. Wang, M. F. Armstrong, R. R. Knowles, J. Am. Chem. Soc. 2013, 135, 17735–17738.
- a) Compound 14c: H. Luo, G. Hu, P. Li, *J. Org. Chem.* 2019, 84, 10569–10578; b) compound 14c:
 J. Tallineau, G. Bashiardes, J.-M. Coustard, F. Lecornué, *Synlett* 2009, 17, 2761–2764.
- ²³ V. J. Olsson, K. J. Szabó *Angew. Chem. Int. Ed.* **2007**, *46*, 6891-6893.